Faculty Collaboration Database

1. Medin JA, Hunt L, Gathy K, Evans RK, Coleman MS. Efficient, low-cost protein factories: expression of human adenosine deaminase in baculovirus-infected insect larvae. Proc Natl Acad Sci U S A. 1990 Apr;87(7):2760-4. PMCID: PMC53770

2. Medin JA, Coleman MS. Lack of functional significance of Cys227 and Cys234 in terminal deoxynucleotidyltransferase. J Biol Chem. 1992 Mar 15;267(8):5199-201.

3. Keller H, Dreyer C., Medin J., Mahfoudi A., Ozato K., and Wahli W. Fatty acids and retinoids control lipid metabolism through activation of PPAR/RXR heterodimers. Proc Natl Acad Sci USA. 90(6):21160-2164(1993).

4. Bhaumik K., Medin J., Gathy K., and Coleman M.S. Mutational analysis of active-site residues of human adenosine deaminase. J Biol Chem. 268(8):5464-5470 (1993).

5. Keller H., Mahfoudi A., Dreyer C., Hihi A.K., Medin J., Ozato K., and Wahli W. Peroxisome proliferator-activated receptors (PPARs) and lipid metabolism. Annals NY Acad Sci 684:157-173 (1993).

6. Segars JH, Nagata T, Bours V, Medin JA, Franzoso G, Blanco JC, Drew PD, Becker KG, An J, Tang T. Retinoic acid induction of major histocompatibility complex class I genes in NTera-2 embryonal carcinoma cells involves induction of NF-kappa B (p50-p65) and retinoic acid receptor beta-retinoid X receptor beta heterodimers. Mol Cell Biol. 1993 Oct;13(10):6157-69. PMCID: PMC364675

7. Krey G., Keller H., Mahfoudi A., Medin J., Ozato K. Dreyer C., and Wahli W. Xenopus peroxisome proliferator activated receptors: Genomic organization, response element recognition, heterodimer formation with RXR, and activation by fatty acids. J Steroid Biochm Mol Biol. 47(1-6):65-73(1993).

8. Lee IJ, Driggers PH, Medin JA, Nikodem VM, Ozato K. Recombinant thyroid hormone receptor and retinoid X receptor stimulate ligand-dependent transcription in vitro. Proc Natl Acad Sci U S A. 1994 Mar 01;91(5):1647-51. PMCID: PMC43220

9. Bovolenta C, Driggers PH, Marks MS, Medin JA, Politis AD, Vogel SN, Levy DE, Sakaguchi K, Appella E, Coligan JE. Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor family. Proc Natl Acad Sci U S A. 1994 May 24;91(11):5046-50. PMCID: PMC43928

10. Medin JA, Minucci S, Driggers PH, Lee IJ, Ozato K. Quantitative increases in DNA binding affinity and positional effects determine 9-cis retinoic acid induced activation of the retinoid X receptor beta homodimer. Mol Cell Endocrinol. 1994 Oct;105(1):27-35.

11. Nunez SB, Medin JA, Keller H, Wang K, Ozato K, Wahli W, Segars J. Retinoid X receptor beta and peroxisome proliferator-activated receptor activate an estrogen response element. Recent Prog Horm Res. 1995;50:409-16.

12. Medin JA, Gathy K, Coleman MS. Expression of foreign proteins in Trichoplusia ni larvae. Methods Mol Biol. 1995;39:265-75.

13. Schiffmann R, Medin JA, Ward JM, Stahl S, Cottler-Fox M, Karlsson S. Transfer of the human glucocerebrosidase gene into hematopoietic stem cells of nonablated recipients: successful engraftment and long-term expression of the transgene. Blood. 1995 Aug 01;86(3):1218-27.

14. Migita M, Medin JA, Pawliuk R, Jacobson S, Nagle JW, Anderson S, Amiri M, Humphries RK, Karlsson S. Selection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors. Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12075-9. PMCID: PMC40299

15. Medin JA, Migita M, Pawliuk R, Jacobson S, Amiri M, Kluepfel-Stahl S, Brady RO, Humphries RK, Karlsson S. A bicistronic therapeutic retroviral vector enables sorting of transduced CD34+ cells and corrects the enzyme deficiency in cells from Gaucher patients. Blood. 1996 Mar 01;87(5):1754-62.

16. Medin JA, Tudor M, Simovitch R, Quirk JM, Jacobson S, Murray GJ, Brady RO. Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7917-22. PMCID: PMC38849

17. Nuñez SB, Medin JA, Braissant O, Kemp L, Wahli W, Ozato K, Segars JH. Retinoid X receptor and peroxisome proliferator-activated receptor activate an estrogen responsive gene independent of the estrogen receptor. Mol Cell Endocrinol. 1997 Mar 14;127(1):27-40.

18. Pemrick SM, Abarzúa P, Kratzeisen C, Marks MS, Medin JA, Ozato K, Grippo JF. Characterization of the chimeric retinoic acid receptor RARalpha/VDR. Leukemia. 1998 Apr;12(4):554-62.

19. Medin JA, Brandt JE, Rozler E, Nelson M, Bartholomew A, Li C, Turian J, Chute J, Chung T, Hoffman R. Ex vivo expansion and genetic marking of primitive human and baboon hematopoietic cells. Ann N Y Acad Sci. 1999 Apr 30;872:233-40; discussion 240-2.

20. Medin J.A., Takenaka T., Caprentier S., Garcia V., Basile J.-P., Segui B., Andrieu-Abadie N., Auge N., Salvayre R., and Levade T. Retroviral-mediated correction of the metabolic defect in cultured Farber disease cells. Hum Gene Ther 10(8):1321-1329 (1999).

21. Medin JA, Takenaka T, Carpentier S, Garcia V, Basile JP, Segui B, Andrieu-Abadie N, Auge N, Salvayre R, Levade T. Retrovirus-mediated correction of the metabolic defect in cultured Farber disease cells. Hum Gene Ther. 1999 May 20;10(8):1321-9.

22. Takenaka T, Hendrickson CS, Tworek DM, Tudor M, Schiffmann R, Brady RO, Medin JA. Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease. Exp Hematol. 1999 Jul;27(7):1149-59.

23. Takenaka T, Qin G, Brady RO, Medin JA. Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease. Hum Gene Ther. 1999 Aug 10;10(12):1931-9.

24. Ségui B, Bezombes C, Uro-Coste E, Medin JA, Andrieu-Abadie N, Augé N, Brouchet A, Laurent G, Salvayre R, Jaffrézou JP, Levade T. Stress-induced apoptosis is not mediated by endolysosomal ceramide. FASEB J. 2000 Jan;14(1):36-47.

25. Takenaka T, Murray GJ, Qin G, Quirk JM, Ohshima T, Qasba P, Clark K, Kulkarni AB, Brady RO, Medin JA. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7515-20. PMCID: PMC16577

26. Qin G, Takenaka T, Telsch K, Kelley L, Howard T, Levade T, Deans R, Howard BH, Malech HL, Brady RO, Medin JA. Preselective gene therapy for Fabry disease. Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3428-33. PMCID: PMC30670

27. Veldman RJ, Maestre N, Aduib OM, Medin JA, Salvayre R, Levade T. A neutral sphingomyelinase resides in sphingolipid-enriched microdomains and is inhibited by the caveolin-scaffolding domain: potential implications in tumour necrosis factor signalling. Biochem J. 2001 May 01;355(Pt 3):859-68. PMCID: PMC1221804

28. Veldman RJ, Mita A, Cuvillier O, Garcia V, Klappe K, Medin JA, Campbell JD, Carpentier S, Kok JW, Levade T. The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs. FASEB J. 2003 Jun;17(9):1144-6.

29. Li J.-H., Shi W., Chia M., Sanchez-Sweatman O., Siatkskas C., Huang D., Busson P., Klamut H., Yew W.C., Richardson C., O'Sullivan B., Gullane P., Neligan P., Medin J.A., and Liu F.-F. Efficacy of targeted FasL in nasopharyngeal carcinoma. Mol Ther 8(6):964-973 (2003).

30. Smith SL, Kiss J, Siatskas C, Medin JA, Moldwin RL. Enhanced effect of vascular endothelial growth factor, thrombopoietin peptide agonist, SCF, and Flt3-L on LTC-IC and reporter gene transduction from umbilical cord blood CD34+ cells. Transfusion. 2004 Mar;44(3):438-49.

31. Yoshimitsu M, Sato T, Tao K, Walia JS, Rasaiah VI, Sleep GT, Murray GJ, Poeppl AG, Underwood J, West L, Brady RO, Medin JA. Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16909-14. PMCID: PMC534735

32. Silvertown JD, Walia JS, Medin JA. Cloning, sequencing and characterization of lentiviral-mediated expression of rhesus macaque (Macaca mulatta) interleukin-2 receptor alpha cDNA. Dev Comp Immunol. 2005;29(11):989-1002.

33. Poeppl AG, Murray GJ, Medin JA. Enhanced filter paper enzyme assay for high-throughput population screening for Fabry disease. Anal Biochem. 2005 Feb 01;337(1):161-3.

34. Medin JA, Liang SB, Hou JW, Kelley LS, Peace DJ, Fowler DH. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo. Cancer Gene Ther. 2005 Jun;12(6):540-51.

35. Lund N, Branch DR, Sakac D, Lingwood CA, Siatskas C, Robinson CJ, Brady RO, Medin JA. Lack of susceptibility of cells from patients with Fabry disease to productive infection with R5 human immunodeficiency virus. AIDS. 2005 Sep 23;19(14):1543-6.

36. Siatskas C, Underwood J, Ramezani A, Hawley RG, Medin JA. Specific pharmacological dimerization of KDR in lentivirally transduced human hematopoietic cells activates anti-apoptotic and proliferative mechanisms. FASEB J. 2005 Oct;19(12):1752-4.

37. Silvertown JD, Ng J, Sato T, Summerlee AJ, Medin JA. H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. Int J Cancer. 2006 Jan 01;118(1):62-73.

38. du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res. 2006 Feb 01;12(3 Pt 1):904-16.

39. Ayach BB, Yoshimitsu M, Dawood F, Sun M, Arab S, Chen M, Higuchi K, Siatskas C, Lee P, Lim H, Zhang J, Cukerman E, Stanford WL, Medin JA, Liu PP. Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2304-9. PMCID: PMC1413746

40. Mattocks M., Bagovich M., DeRosa M., Bond S., Binnington B., Rasaiah V.I., Medin J., and Lingwood C. Treatment of neutral glyocosphingolipid lysosomal storage disease via inhibition of the ABC Drug Transporter, MDR1. Cyclosporin A can lower serum and liver globotriaosyl ceramide levels in the Fabry mouse model. FEBS J.273(9):2064-2075 (2006)

41. Silvertown JD, Walia JS, Summerlee AJ, Medin JA. Functional expression of mouse relaxin and mouse relaxin-3 in the lung from an Ebola virus glycoprotein-pseudotyped lentivirus via tracheal delivery. Endocrinology. 2006 Aug;147(8):3797-808.

42. Yoshimitsu M, Higuchi K, Dawood F, Rasaiah VI, Ayach B, Chen M, Liu P, Medin JA. Correction of cardiac abnormalities in fabry mice by direct intraventricular injection of a recombinant lentiviral vector that engineers expression of alpha-galactosidase A. Circ J. 2006 Nov;70(11):1503-8.

43. Yoshimitsu M, Higuchi K, Ramsubir S, Nonaka T, Rasaiah VI, Siatskas C, Liang SB, Murray GJ, Brady RO, Medin JA. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Gene Ther. 2007 Feb;14(3):256-65.

44. Liang SB, Yoshimitsu M, Poeppl A, Rasaiah VI, Cai J, Fowler DH, Medin JA. Multiple reduced-intensity conditioning regimens facilitate correction of Fabry mice after transplantation of transduced cells. Mol Ther. 2007 Mar;15(3):618-27.

45. Silvertown JD, Symes JC, Neschadim A, Nonaka T, Kao JC, Summerlee AJ, Medin JA. Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB J. 2007 Mar;21(3):754-65.

46. Thomson CW, Mossoba ME, Siatskas C, Chen W, Sung A, Medin JA, Zhang L. Lentivirally transduced recipient-derived dendritic cells serve to ex vivo expand functional FcRgamma-sufficient double-negative regulatory T cells. Mol Ther. 2007 Apr;15(4):818-24.

47. Sato T, Neschadim A, Konrad M, Fowler DH, Lavie A, Medin JA. Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther. 2007 May;15(5):962-70.

48. Ramsubir S, Yoshimitsu M, Medin JA. Anti-CD25 targeted killing of bicistronically transduced cells: a novel safety mechanism against retroviral genotoxicity. Mol Ther. 2007 Jun;15(6):1174-81.

49. Formigli L., Perna A.-M., Meacci E., Cinci L., Margheri M., Nistri S., Tani A., Silvertown J., Orlandini G., Porciani C., Zecchi-Orlandini S., Medin J., and Bani D. Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodeling. J Cell Mol Med. 11(5):1087-1100 (2007).

50. Bastianutto C., Mian A., Symes J., Mocanu J. Alajez N., Sleep G., Shi W., Keating A., Crump M. Gospodarowiez M., Medin J., Minden M., and Liu, F.-F. Local radiotherapy induces homing of hematopoietic stem cells to the irradiated bone marrow. Cancer Res 67(21): 10112-10116(2007).

51. Mossoba ME, Walia JS, Rasaiah VI, Buxhoeveden N, Head R, Ying C, Foley JE, Bramson JL, Fowler DH, Medin JA. Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol Ther. 2008 Mar;16(3):607-17.

52. Rasaiah V.I., Underwood J.P., Oreopoulos D.G., and Medin J.A., Implementation of high-throughput screening for Fabry disease in Toronto dialysis patients. NDT Plus. 1(2):129-130 (2008). doi: 10.1093/ndplus/sfn009

53. Symes JC, Kurin M, Fleshner NE, Medin JA. Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel. Mol Cancer Ther. 2008 Sep;7(9):3018-28.

54. Francia G, Emmenegger U, Lee CR, Shaked Y, Folkins C, Mossoba M, Medin JA, Man S, Zhu Z, Witte L, Kerbel RS. Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines. Mol Cancer Ther. 2008 Oct;7(10):3452-9.

55. Ramsubir S, Nonaka T, Girbés CB, Carpentier S, Levade T, Medin JA. In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease. Mol Genet Metab. 2008 Nov;95(3):133-41. PMCID: PMC2614354

56. Surzyn M, Symes J, Medin JA, Sefton MV. IL-10 secretion increases signal persistence of HEMA-MMA-microencapsulated luciferase-modified CHO fibroblasts in mice. Tissue Eng Part A. 2009 Jan;15(1):127-36.

57. Higuchi K, Ayach B, Sato T, Chen M, Devine SP, Rasaiah VI, Dawood F, Yanagisawa T, Tei C, Takenaka T, Liu PP, Medin JA. Direct injection of kit ligand-2 lentivirus improves cardiac repair and rescues mice post-myocardial infarction. Mol Ther. 2009 Feb;17(2):262-8. PMCID: PMC2835055

58. Symes J, Evangelou A, Ignatchenko A, Fleshner N, Kislinger T, Medin JA. Multidimensional protein identification technology analysis highlights mitoxantrone-induced expression modulations in the primary prostate cancer cell proteome. Proteomics Clin Appl. 2009 Mar;3(3):347-58.

59. Loisel-Meyer S, Felizardo T, Mariotti J, Mossoba ME, Foley JE, Kammerer R, Mizue N, Keefe R, McCart JA, Zimmermann W, Dropulic B, Fowler DH, Medin JA. Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection. Mol Cancer Ther. 2009 Mar;8(3):692-702. PMCID: PMC2846382

60. Symes JC, Siatskas C, Fowler DH, Medin JA. Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells. Cancer Gene Ther. 2009 May;16(5):439-52. PMCID: PMC2857530

61. Rodriguez-Sosa JR, Silvertown JD, Foster RA, Medin JA, Hahnel A. Transduction and transplantation of spermatogonia into the testis of ram lambs through the extra-testicular rete. Reprod Domest Anim. 2009 Aug;44(4):612-20.

62. Labbe A, Nelles M, Walia J, Jia L, Furlonger C, Nonaka T, Medin JA, Paige CJ. IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy. J Cell Mol Med. 2009 Aug;13(8B):1962-1976. PMCID: PMC6512371

63. Sato T, Ramsubir S, Higuchi K, Yanagisawa T, Medin JA. Vascular endothelial growth factor broadens lentivector distribution in the heart after neonatal injection. J Cardiol. 2009 Oct;54(2):245-54.

64. Maekawa Y, Mizue N, Chan A, Shi Y, Liu Y, Dawood S, Chen M, Dawood F, de Couto G, Li GH, Suzuki N, Yeh WC, Gramolini A, Medin JA, Liu PP. Survival and cardiac remodeling after myocardial infarction are critically dependent on the host innate immune interleukin-1 receptor-associated kinase-4 signaling: a regulator of bone marrow-derived dendritic cells. Circulation. 2009 Oct 06;120(14):1401-14.

65. Francia G, Man S, Lee CJ, Lee CR, Xu P, Mossoba ME, Emmenegger U, Medin JA, Kerbel RS. Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clin Cancer Res. 2009 Oct 15;15(20):6358-66. PMCID: PMC2788792

66. Cypel M. Liu M., Rubacha M., Yeung J.C., Hirayama S., Anraku M., Sato M., Medin J., Davidson B.L., de Perrot M.,Waddell T.K., Slutsky A.S., and Keshavjee S. Functional repair of human donor lungs by IL-10 gene therapy.

67. Silvertown JD, Neschadim A, Liu HN, Shannon P, Walia JS, Kao JC, Robertson J, Summerlee AJ, Medin JA. Relaxin-3 and receptors in the human and rhesus brain and reproductive tissues. Regul Pept. 2010 Jan 08;159(1-3):44-53.

68. Higuchi K, Yoshimitsu M, Fan X, Guo X, Rasaiah VI, Yen J, Tei C, Takenaka T, Medin JA. Alpha-galactosidase A-Tat fusion enhances storage reduction in hearts and kidneys of Fabry mice. Mol Med. 2010;16(5-6):216-21. PMCID: PMC2864812

69. Drake RR, Elschenbroich S, Lopez-Perez O, Kim Y, Ignatchenko V, Ignatchenko A, Nyalwidhe JO, Basu G, Wilkins CE, Gjurich B, Lance RS, Semmes OJ, Medin JA, Kislinger T. In-depth proteomic analyses of direct expressed prostatic secretions. J Proteome Res. 2010 May 07;9(5):2109-16. PMCID: PMC2869496

70. Fan X, Lang H, Zhou X, Zhang L, Yin R, Maciejko J, Giannitsos V, Motyka B, Medin JA, Platt JL, West LJ. Induction of human blood group a antigen expression on mouse cells, using lentiviral gene transduction. Hum Gene Ther. 2010 Jul;21(7):877-90. PMCID: PMC2938359

71. Likar Y, Zurita J, Dobrenkov K, Shenker L, Cai S, Neschadim A, Medin JA, Sadelain M, Hricak H, Ponomarev V. A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs. J Nucl Med. 2010 Sep;51(9):1395-403. PMCID: PMC4405132

72. Romieu-Mourez R, François M, Abate A, Boivin MN, Birman E, Bailey D, Bramson JL, Forner K, Young YK, Medin JA, Galipeau J. Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming. Cancer Res. 2010 Oct 15;70(20):7742-7.

73. Lee CJ, Fan X, Guo X, Medin JA. Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease. J Cardiol. 2011 Jan;57(1):115-22.

74. Siegers GM, Felizardo TC, Mathieson AM, Kosaka Y, Wang XH, Medin JA, Keating A. Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ leukemia model. PLoS One. 2011 Feb 03;6(2):e16700. PMCID: PMC3033392

75. Wang AY, Crome SQ, Jenkins KM, Medin JA, Bramson JL, Levings MK. Adenoviral-transduced dendritic cells are susceptible to suppression by T regulatory cells and promote interleukin 17 production. Cancer Immunol Immunother. 2011 Mar;60(3):381-8. PMCID: PMC11028621

76. Tsunooka N, Hirayama S, Medin JA, Liles WC, Keshavjee S, Waddell TK. A novel tissue-engineered approach to problems of the postpneumonectomy space. Ann Thorac Surg. 2011 Mar;91(3):880-6.

77. Yoshimitsu M, Higuchi K, Miyata M, Devine S, Mattman A, Sirrs S, Medin JA, Tei C, Takenaka T. Identification of novel mutations in the α-galactosidase A gene in patients with Fabry disease: pitfalls of mutation analyses in patients with low α-galactosidase A activity. J Cardiol. 2011 May;57(3):345-53.

78. Yoshimitsu M, Higuchi K, Fan X, Takao S, Medin JA, Tei C, Takenaka T. Sequencing and characterization of the porcine α-galactosidase A gene: towards the generation of a porcine model for Fabry disease. Mol Biol Rep. 2011 Jun;38(5):3145-52.

79. Walia JS, Neschadim A, Lopez-Perez O, Alayoubi A, Fan X, Carpentier S, Madden M, Lee CJ, Cheung F, Jaffray DA, Levade T, McCart JA, Medin JA. Autologous transplantation of lentivector/acid ceramidase-transduced hematopoietic cells in nonhuman primates. Hum Gene Ther. 2011 Jun;22(6):679-87. PMCID: PMC3155125

80. Siegers GM, Dhamko H, Wang XH, Mathieson AM, Kosaka Y, Felizardo TC, Medin JA, Tohda S, Schueler J, Fisch P, Keating A. Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy. 2011 Jul;13(6):753-64.

81. Felizardo TC, Wang JC, McGray RA, Evelegh C, Spaner DE, Fowler DH, Bramson JL, Medin JA. Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model. Gene Ther. 2011 Oct;18(10):986-95. PMCID: PMC6948845

82. Hirayama S, Sato M, Liu M, Loisel-Meyer S, Yeung JC, Wagnetz D, Cypel M, Zehong G, Medin JA, Keshavjee S. Local long-term expression of lentivirally delivered IL-10 in the lung attenuates obliteration of intrapulmonary allograft airways. Hum Gene Ther. 2011 Nov;22(11):1453-60.

83. Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V, Foley JE, Massey PR, Felizardo TC, Riley JL, Levine BL, June CH, Medin JA, Fowler DH. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med. 2011 Nov 30;3(111):111ra120. PMCID: PMC3235958

84. Neschadim A, Wang JC, Sato T, Fowler DH, Lavie A, Medin JA. Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase. Mol Ther. 2012 May;20(5):1002-13. PMCID: PMC3345984

85. Scaife M, Pacienza N, Au BC, Wang JC, Devine S, Scheid E, Lee CJ, Lopez-Perez O, Neschadim A, Fowler DH, Foley R, Medin JA. Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes. Gene Ther. 2013 Jan;20(1):24-34.

86. Swift BE, Williams BA, Kosaka Y, Wang XH, Medin JA, Viswanathan S, Martinez-Lopez J, Keating A. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica. 2012 Jul;97(7):1020-8. PMCID: PMC3396673

87. Berthod F, Symes J, Tremblay N, Medin JA, Auger FA. Spontaneous fibroblast-derived pericyte recruitment in a human tissue-engineered angiogenesis model in vitro. J Cell Physiol. 2012 May;227(5):2130-7.

88. Principe S, Kim Y, Fontana S, Ignatchenko V, Nyalwidhe JO, Lance RS, Troyer DA, Alessandro R, Semmes OJ, Kislinger T, Drake RR, Medin JA. Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J Proteome Res. 2012 Apr 06;11(4):2386-96. PMCID: PMC3642074

89. Pacienza N, Yoshimitsu M, Mizue N, Au BC, Wang JC, Fan X, Takenaka T, Medin JA. Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD/SCID/Fabry mice. Mol Ther. 2012 Jul;20(7):1454-61. PMCID: PMC3393855

90. Neschadim A, Wang JC, Lavie A, Medin JA. Bystander killing of malignant cells via the delivery of engineered thymidine-active deoxycytidine kinase for suicide gene therapy of cancer. Cancer Gene Ther. 2012 May;19(5):320-7.

91. Kim Y, Ignatchenko V, Yao CQ, Kalatskaya I, Nyalwidhe JO, Lance RS, Gramolini AO, Troyer DA, Stein LD, Boutros PC, Medin JA, Semmes OJ, Drake RR, Kislinger T. Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics. 2012 Dec;11(12):1870-84. PMCID: PMC3518113

92. Sun Z, Lee CJ, Mejia-Guerrero S, Zhang Y, Higuchi K, Li RK, Medin JA. Neonatal transfer of membrane-bound stem cell factor improves survival and heart function in aged mice after myocardial ischemia. Hum Gene Ther. 2012 Dec;23(12):1280-9.

93. Yannarelli G., Dayan V., Pacienza N., Lee C.-J., Medin J., and Keating A. Human umbilical cord perivascular cells exhibit enhanced cardiomyocyte reprogramming and cardiac function after experimental acute myocardial infarction. Cell Transplant [Epub ahead of print] (2012).

94. Yannarelli G., Pacienza N., Cuniberti L., Medin J., Davies J., and Keating A. Brief Report: The potential role of epigenetics on multipotent cell differentiation capacity of mesenchymal stromal cells. Stem Cells 31(1)215-220 (2013).

95. Payne NL, Sun G, McDonald C, Moussa L, Emerson-Webber A, Loisel-Meyer S, Medin JA, Siatskas C, Bernard CC. Human adipose-derived mesenchymal stem cells engineered to secrete IL-10 inhibit APC function and limit CNS autoimmunity. Brain Behav Immun. 2013 May;30:103-14.

96. Hirayama S, Sato M, Loisel-Meyer S, Matsuda Y, Oishi H, Guan Z, Saito T, Yeung J, Cypel M, Hwang DM, Medin JA, Liu M, Keshavjee S. Lentivirus IL-10 gene therapy down-regulates IL-17 and attenuates mouse orthotopic lung allograft rejection. Am J Transplant. 2013 Jun;13(6):1586-93.

97. Felizardo TC, Foley J, Steed K, Dropulic B, Amarnath S, Medin JA, Fowler DH. Harnessing autophagy for cell fate control gene therapy. Autophagy. 2013 Jul;9(7):1069-79. PMCID: PMC3722316

98. Alayoubi AM, Wang JC, Au BC, Carpentier S, Garcia V, Dworski S, El-Ghamrasni S, Kirouac KN, Exertier MJ, Xiong ZJ, Privé GG, Simonaro CM, Casas J, Fabrias G, Schuchman EH, Turner PV, Hakem R, Levade T, Medin JA. Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med. 2013 Jun;5(6):827-42. PMCID: PMC3779446

99. Wang JC, Felizardo TC, Au BC, Fowler DH, Dekaban GA, Medin JA. Engineering lentiviral vectors for modulation of dendritic cell apoptotic pathways. Virol J. 2013 Jul 20;10:240. PMCID: PMC3723442

100. Sato T, Neschadim A, Lavie A, Yanagisawa T, Medin JA. The engineered thymidylate kinase (TMPK)/AZT enzyme-prodrug axis offers efficient bystander cell killing for suicide gene therapy of cancer. PLoS One. 2013;8(10):e78711. PMCID: PMC3806853

101. Wei LZ, Xu Y, Nelles EM, Furlonger C, Wang JC, Di Grappa MA, Khokha R, Medin JA, Paige CJ. Localized interleukin-12 delivery for immunotherapy of solid tumours. J Cell Mol Med. 2013 Nov;17(11):1465-74. PMCID: PMC4117559

102. Jones EE, Dworski S, Canals D, Casas J, Fabrias G, Schoenling D, Levade T, Denlinger C, Hannun YA, Medin JA, Drake RR. On-tissue localization of ceramides and other sphingolipids by MALDI mass spectrometry imaging. Anal Chem. 2014 Aug 19;86(16):8303-11. PMCID: PMC4139181

103. Nelles ME, Moreau JM, Furlonger CL, Berger A, Medin JA, Paige CJ. Murine splenic CD4⁺ T cells, induced by innate immune cell interactions and secreted factors, develop antileukemia cytotoxicity. Cancer Immunol Res. 2014 Nov;2(11):1113-24.

104. Sato T, Neschadim A, Nakagawa R, Yanagisawa T, Medin JA. Evaluation of Bystander Cell Killing Effects in Suicide Gene Therapy of Cancer: Engineered Thymidylate Kinase (TMPK)/AZT Enzyme-Prodrug Axis. Methods Mol Biol. 2015;1317:55-67.

105. Dworski S, Berger A, Furlonger C, Moreau JM, Yoshimitsu M, Trentadue J, Au BC, Paige CJ, Medin JA. Markedly perturbed hematopoiesis in acid ceramidase deficient mice. Haematologica. 2015 May;100(5):e162-5. PMCID: PMC4420221

106. Au B.C., Lee C-J., Lopez-Perez O., Foltz W., Felizardo T.C., Wang J.C.M., Huang J., Fan X., Madden M., Goldstein A., Jaffray D.A., Moloo B., McCart J.A., and Medin J.A. Direct lymph node vaccination of Lentivector/Prostate-Specific Antigen is safe and generates tissue specific responses in rhesus macaques. Biomedicines 4,6:doi:10.3390/biomedicines4010006 (2016)

107. Provençal P, Boutin M, Dworski S, Au B, Medin JA, Auray-Blais C. Relative distribution of Gb3 isoforms/analogs in NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry. Bioanalysis. 2016 Sep;8(17):1793-807. PMCID: PMC4992964

108. Kamani M, Provencal P., Boutin M., Pacienza N., Fan X., Novak A., Huang T.C., Binnington B., Au B.C., Auray-Blais C., Lingwood C.A., and Medin J.A. Glycosphingolipid storage in Fabry mice extends beyond globotriosylceramide and is affected by ABCB1 depletion. Future Science OA. 2016 Oct 13;2(4): FSO147 doi10.4155/fsoa-2016-0027 PMID 28116130.

109. Huang J., Liu Y., Au B.C., Barber D.L., Arruda A., Schambach A., Rothe M., Minden M. Paige C.J. and Medin J.A. Preclinical Validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML. Mol Ther p Methods and Clinical Development(in press).

110. Kamani, M., Provencal, P., Boutin, M., Pacienza, N., Fan, X., Guo, C., Binnington, B., Novak, A., Auray-Blais, C., Lingwood, C.A., and Medin, J.A.: Complex role of ABCB1 in glycosphingolipid synthesis in the Fabry mouse. (submitted).

111. Dworski S., Lu P., Khan A., Maranda B., Mitchell J., Parini R., Di Rocco M., Hugle B., Yoshimitsu M., Schuchman E.H., Norris J.S., Levade T., and Medin J.A. Altered cytokine and ceramide metabolite levels in plasma from Farber mice and Farber patients (under revision).

112. Sikora J., Dworski S., Jones E.E., Kamani M.A., Micsenyi M.C., Sawada T., Le Faouder P., Bertrand-Michel J., Dupuy A., Dunn C.K., Xuan I.C.Y., Casas J., Fabrias G., Hampson D.R., Levade T., Drake R.R., Medin J.A. and Walkley S.U. Acid ceramidase deficiency in mice results in broad range of central nervous system abnormalities (under revisions.

113. Yu, F., Islam, D., Belcastro, R., Carpentier, S., Casas, J., Fabrias, G., Levade, T., Tanswell, K., Zhang, H., and Medin, J.A.: Impaired lung mechanics in the acid ceramidase deficient mouse (manuscript in preparation).

114. Au, B.C., Liu, Y., Huang, J., Nelles, M., Arruda, A., Rothe, M., Paul, G., Schambach, A., Barber, D., Minden, M., Paige, C., and Medin, J.A.: Pre-clinical preparation and validation of tumor cell-based IL-12 immunotherapy for Acute Myeloid Leukemia (manuscript in preparation).

115. Khan, A., Au, B.C., Huang, J., Dworski, S., O’Hoski, P., Prokopishyn, N., Rothe, M., Paul, G., Bischof, D., Nagree, M., Vazquez, L.L., Viswanathan, S., Sirrs, S., Auray-Blais, C., Morel, C., Raiman, J., Schambach, A., West, M., Rupar, T., Keating, A., Cornetta, K., Foley, R., and Medin, J.A.: Pre-clinical safety and efficacy of lentiviral vector–transduced patient CD34+ hematopoietic stem cells for gene therapy of Fabry disease (manuscript in preparation).

116. Dworski, S., Kamani, M., Jones, E.E., Le Faouder, P., Bertrand-Michel, J., Dupuy, A., Ying, S., Grabowski, G., Casas, J., Fabrias, G., Levade, T., Drake, R.R., and Medin, J.A.:. Ceramide species identity, quantity, and localization are affected by acid ceramidase deficiency in the adult mouse brain. (manuscript in preparation).

117. Medin JA. Roscoe Owen Brady: Passion for patients. Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11644-11645. PMCID: PMC5081591

118. Desnick RJ, Barton NW, Furbish S, Grabowski GA, Karlsson S, Kolodny EH, Medin JA, Murray GJ, Mistry PK, Patterson MC, Schiffmann R, Weinreb NJ. Roscoe Owen Brady, MD: Remembrances of co-investigators and colleagues. Mol Genet Metab. 2017;120(1-2):1-7.

119. Dworski S, Lu P, Khan A, Maranda B, Mitchell JJ, Parini R, Di Rocco M, Hugle B, Yoshimitsu M, Magnusson B, Makay B, Arslan N, Guelbert N, Ehlert K, Jarisch A, Gardner-Medwin J, Dagher R, Terreri MT, Lorenco CM, Barillas-Arias L, Tanpaiboon P, Solyom A, Norris JS, He X, Schuchman EH, Levade T, Medin JA. Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy. Biochim Biophys Acta Mol Basis Dis. 2017 Feb;1863(2):386-394. PMCID: PMC7192210

120. Huang J, Liu Y, Au BC, Barber DL, Arruda A, Schambach A, Rothe M, Minden MD, Paige CJ, Medin JA. Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML. Mol Ther Methods Clin Dev. 2016;3:16074. PMCID: PMC5142463

121. He X, Dworski S, Zhu C, DeAngelis V, Solyom A, Medin JA, Simonaro CM, Schuchman EH. Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice. BBA Clin. 2017 Jun;7:85-96. PMCID: PMC5338723

122. Kamani MA, Provençal P, Boutin M, Pacienza N, Fan X, Novak A, Huang TC, Binnington B, Au BC, Auray-Blais C, Lingwood CA, Medin JA. Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion. Future Sci OA. 2016 Dec;2(4):FSO147. PMCID: PMC5242178

123. Thomson CW, Mossoba ME, Siatskas C, Chen W, Sung A, Medin JA, Zhang L. Lentivirally Transduced Recipient-derived Dendritic Cells Serve to Ex Vivo Expand Functional FcRγ-sufficient Double-negative Regulatory T Cells. Mol Ther. 2007 Apr;15(4):818-824.

124. Sikora J, Dworski S, Jones EE, Kamani MA, Micsenyi MC, Sawada T, Le Faouder P, Bertrand-Michel J, Dupuy A, Dunn CK, Xuan ICY, Casas J, Fabrias G, Hampson DR, Levade T, Drake RR, Medin JA, Walkley SU. Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities. Am J Pathol. 2017 Apr;187(4):864-883. PMCID: PMC5397689

125. Oldham RAA, Medin JA. Practical considerations for chimeric antigen receptor design and delivery. Expert Opin Biol Ther. 2017 Aug;17(8):961-978.

126. Nomura R, Sato T, Sato Y, Medin JA, Kushimoto S, Yanagisawa T. Azidothymidine-triphosphate impairs mitochondrial dynamics by disrupting the quality control system. Redox Biol. 2017 Oct;13:407-417. PMCID: PMC5498287

127. Huang J, Khan A, Au BC, Barber DL, López-Vásquez L, Prokopishyn NL, Boutin M, Rothe M, Rip JW, Abaoui M, Nagree MS, Dworski S, Schambach A, Keating A, West ML, Klassen J, Turner PV, Sirrs S, Rupar CA, Auray-Blais C, Foley R, Medin JA. Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34⁺ Cells for Correction of Fabry Disease. Mol Ther Methods Clin Dev. 2017 Jun 16;5:241-258. PMCID: PMC5453867

128. Au BC, Lee CJ, Lopez-Perez O, Foltz W, Felizardo TC, Wang JCM, Huang J, Fan X, Madden M, Goldstein A, Jaffray DA, Moloo B, McCart JA, Medin JA. Direct Lymph Node Vaccination of Lentivector/Prostate-Specific Antigen is Safe and Generates Tissue-Specific Responses in Rhesus Macaques. Biomedicines. 2016 Feb 19;4(1). PMCID: PMC5344243

129. Rasaiah VI, Underwood JP, Oreopoulos DG, Medin JA. Implementation of high-throughput screening for Fabry disease in Toronto dialysis patients. NDT Plus. 2008 Apr;1(2):129-130. PMCID: PMC5477914

130. Molino S, Tate E, McKillop WM, Medin JA. Sphingolipid pathway enzymes modulate cell fate and immune responses. Immunotherapy. 2017 Nov;9(14):1185-1198.

131. Yu FPS, Islam D, Sikora J, Dworski S, Gurka J, López-Vásquez L, Liu M, Kuebler WM, Levade T, Zhang H, Medin JA. Chronic lung injury and impaired pulmonary function in a mouse model of acid ceramidase deficiency. Am J Physiol Lung Cell Mol Physiol. 2018 Mar 01;314(3):L406-L420. PMCID: PMC5900354

132. Broglie L, Margolis D, Medin JA. Yin and Yang of mesenchymal stem cells and aplastic anemia. World J Stem Cells. 2017 Dec 26;9(12):219-226. PMCID: PMC5746642

133. Yu FPS, Dworski S, Medin JA. Deletion of MCP-1 Impedes Pathogenesis of Acid Ceramidase Deficiency. Sci Rep. 2018 Jan 29;8(1):1808. PMCID: PMC5789088

134. Fougerat A, Pan X, Smutova V, Heveker N, Cairo CW, Issad T, Larrivée B, Medin JA, Pshezhetsky AV. Neuraminidase 1 activates insulin receptor and reverses insulin resistance in obese mice. Mol Metab. 2018 Jun;12:76-88. PMCID: PMC6001920

135. Filomeno PA, Kim KP, Yoon N, Rashedi I, Dayan V, Kandel RA, Wang XH, Felizardo TC, Berinstein E, Jelveh S, Filomeno A, Medin JA, Ferguson PC, Keating A. Human mesenchymal stromal cells do not promote recurrence of soft tissue sarcomas in mouse xenografts after radiation and surgery. Cytotherapy. 2018 Aug;20(8):1001-1012.

136. Oishi H, Juvet SC, Martinu T, Sato M, Medin JA, Liu M, Keshavjee S. A novel combined ex vivo and in vivo lentiviral interleukin-10 gene delivery strategy at the time of transplantation decreases chronic lung allograft rejection in mice. J Thorac Cardiovasc Surg. 2018 Sep;156(3):1305-1315.

137. Yu FPS, Amintas S, Levade T, Medin JA. Acid ceramidase deficiency: Farber disease and SMA-PME. Orphanet J Rare Dis. 2018 Jul 20;13(1):121. PMCID: PMC6053731

138. Yu FPS, Sajdak BS, Sikora J, Salmon AE, Nagree MS, Gurka J, Kassem IS, Lipinski DM, Carroll J, Medin JA. Acid Ceramidase Deficiency in Mice Leads to Severe Ocular Pathology and Visual Impairment. Am J Pathol. 2019 Feb;189(2):320-338. PMCID: PMC6412726

139. Neschadim A, Medin JA. Engineered Thymidine-Active Deoxycytidine Kinase for Bystander Killing of Malignant Cells. Methods Mol Biol. 2019;1895:149-163.

140. Liu M, Juvet SC, Medin JA, Martinu T, Oishi H, Keshavjee S. Lentiviral interleukin-10 gene therapy: Safety and questions. J Thorac Cardiovasc Surg. 2019 Feb;157(2):818-819.

141. Yu FPS, Molino S, Sikora J, Rasmussen S, Rybova J, Tate E, Geurts AM, Turner PV, Mckillop WM, Medin JA. Hepatic pathology and altered gene transcription in a murine model of acid ceramidase deficiency. Lab Invest. 2019 Oct;99(10):1572-1592.

142. Nagree MS, Scalia S, McKillop WM, Medin JA. An update on gene therapy for lysosomal storage disorders. Expert Opin Biol Ther. 2019 Jul;19(7):655-670.

143. Dubot P, Sabourdy F, Rybova J, Medin JA, Levade T. Inherited monogenic defects of ceramide metabolism: Molecular bases and diagnoses. Clin Chim Acta. 2019 Aug;495:457-466.

144. Islam, D. Huang, Y., Fanelli, V., Delsedime, L., Wu, S., Khang, J., Han, B., Grassi, A., Li, M., Xu, Y., Luo, A., Wu, J., Liu, X., Mckillop, M., Medin, J., Qiu, H., Zhong, N., Liu, M., Laffey, J., Li, Y., and Zhang, H.: Identification and modulation of microenvironment is crucial for effective mesenchymal stromal cell therapy in acute lung injury. Am J Respir Crit Care Med. 2019 May 15;199(10):1214-1224

145. Islam D, Huang Y, Fanelli V, Delsedime L, Wu S, Khang J, Han B, Grassi A, Li M, Xu Y, Luo A, Wu J, Liu X, McKillop M, Medin J, Qiu H, Zhong N, Liu M, Laffey J, Li Y, Zhang H. Identification and Modulation of Microenvironment Is Crucial for Effective Mesenchymal Stromal Cell Therapy in Acute Lung Injury. Am J Respir Crit Care Med. 2019 May 15;199(10):1214-1224.

146. Li Y, Xu Y, Benitez BA, Nagree MS, Dearborn JT, Jiang X, Guzman MA, Woloszynek JC, Giaramita A, Yip BK, Elsbernd J, Babcock MC, Lo M, Fowler SC, Wozniak DF, Vogler CA, Medin JA, Crawford BE, Sands MS. Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target. Proc Natl Acad Sci U S A. 2019 Oct 01;116(40):20097-20103. PMCID: PMC6778236

147. Nanbakhsh A, Best B, Riese M, Rao S, Wang L, Medin J, Thakar MS, Malarkannan S. Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells. J Vis Exp. 2018 Jan 15(131). PMCID: PMC5908645

148. Ellen Jones E, Dworski S, Kamani M, Canals D, Wada M, Liu X, Hannun YA, Norris J, Medin JA, Drake RR. Detection and distribution of sphingolipids in tissue by FTICR MALDI-imaging mass spectrometry Bioactive Sphingolipids in Cancer Biology and Therapy. August 28, 2015:339-358.

149. Yannarelli G, Pacienza N, Cuniberti L, Medin J, Davies J, Keating A. Brief report: The potential role of epigenetics on multipotent cell differentiation capacity of mesenchymal stromal cells. Stem Cells. 2013 Jan;31(1):215-20.

150. Yannarelli G, Dayan V, Pacienza N, Lee CJ, Medin J, Keating A. Human umbilical cord perivascular cells exhibit enhanced cardiomyocyte reprogramming and cardiac function after experimental acute myocardial infarction. Cell Transplant. 2013;22(9):1651-66.

151. Medin J, Fowler D. Experimental and applied immunotherapy Experimental and Applied Immunotherapy. 2011:1-442.

152. . Radiation therapy and cancer treatment: From the basics to combination therapies that ignite immunity Experimental and Applied Immunotherapy. 2011:357-388.

153. Moretti A, Jaffray DA, Medin JA. Radiation therapy and cancer treatment: From the basics to combination therapies that ignite immunity Experimental and Applied Immunotherapy. 2011:357-388.

154. Cypel M, Liu M, Rubacha M, Yeung JC, Hirayama S, Anraku M, Sato M, Medin J, Davidson BL, de Perrot M, Waddell TK, Slutsky AS, Keshavjee S. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med. 2009 Oct 28;1(4):4ra9.

155. Medin JA. Molecular Therapeutics in Hematology: Gene Therapy Molecular Hematology: Third Edition. 10 March 2010:318-335.

156. Bastianutto C, Mian A, Symes J, Mocanu J, Alajez N, Sleep G, Shi W, Keating A, Crump M, Gospodarowicz M, Medin J, Minden M, Liu FF. Local radiotherapy induces homing of hematopoietic stem cells to the irradiated bone marrow. Cancer Res. 2007 Nov 01;67(21):10112-6.

157. Berger A, Colpitts SJ, Seabrook MSS, Furlonger CL, Bendix MB, Moreau JM, McKillop WM, Medin JA, Paige CJ. Interleukin-15 in cancer immunotherapy: IL-15 receptor complex versus soluble IL-15 in a cancer cell-delivered murine leukemia model. J Immunother Cancer. 2019 Dec 19;7(1):355. PMCID: PMC6924073

158. Formigli L, Perna AM, Meacci E, Cinci L, Margheri M, Nistri S, Tani A, Silvertown J, Orlandini G, Porciani C, Zecchi-Orlandini S, Medin J, Bani D. Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodelling. J Cell Mol Med. 2007;11(5):1087-100. PMCID: PMC4401276

159. Mattocks M, Bagovich M, De Rosa M, Bond S, Binnington B, Rasaiah VI, Medin J, Lingwood C. Treatment of neutral glycosphingolipid lysosomal storage diseases via inhibition of the ABC drug transporter, MDR1. Cyclosporin A can lower serum and liver globotriaosyl ceramide levels in the Fabry mouse model. FEBS J. 2006 May;273(9):2064-75.

160. Khatami S, Rendon A, Yoshimitsu M, Medin J, Lilge L. Effect of GFP expression on the sensitivity of glioma cell lines to photodynamic therapy Progress in Biomedical Optics and Imaging - Proceedings of SPIE. 2005;5969.

161. Li JH, Shi W, Chia M, Sanchez-Sweatman O, Siatskas C, Huang D, Busson P, Klamut H, Yeh WC, Richardson C, O'Sullivan B, Gullane P, Neligan P, Medin J, Liu FF. Efficacy of targeted FasL in nasopharyngeal carcinoma. Mol Ther. 2003 Dec;8(6):964-73.

162. Medin JA. Vector divergence to convergence? Gene Therapy. August 2003;10(17):1407.

163. Takcnaka T, Hendrickson CS, Tudor M, Schulmann R, Brady RO, Medin JA. Extending metabolic cooperativity in gene transfer for fabry disease: Transduction of patient bone marrow cells leads to intracellular enzymatic correction and secretion FASEB Journal. 1997;11(9).

164. Medin JA, Tudor M, Simovitch R, Quirk JM, Tacobson S, Murray GJ, Brady RO. Gene therapy for fabry disease: Expression, secretion and uptake of a-galactosidase a (α-gal A) driven by a high titer recombinant retroviral vector FASEB Journal. 1996;10(6).

165. Krey G, Keller H, Mahfoudi A, Medin J, Ozato K, Dreyer C, Wahli W. Xenopus peroxisome proliferator activated receptors: genomic organization, response element recognition, heterodimer formation with retinoid X receptor and activation by fatty acids. J Steroid Biochem Mol Biol. 1993 Dec;47(1-6):65-73.

166. Keller H, Mahfoudi A, Dreyer C, Hihi AK, Medin J, Ozato K, Wahli W. Peroxisome proliferator-activated receptors and lipid metabolism. Ann N Y Acad Sci. 1993 Jun 11;684:157-73.

167. Bhaumik D, Medin J, Gathy K, Coleman MS. Mutational analysis of active site residues of human adenosine deaminase. J Biol Chem. 1993 Mar 15;268(8):5464-70.

168. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2160-4. PMCID: PMC46045

169. Bayerle A, Marsching C, Rabionet M, Dworski S, Kamani MA, Chitraju C, Gluchowski NL, Gabriel KR, Herzer S, Jennemann R, Levade T, Medin JA, Sandhoff R. Endogenous levels of 1-O-acylceramides increase upon acidic ceramidase deficiency and decrease due to loss of Dgat1 in a tissue-dependent manner. Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Sep;1865(9):158741.

170. Oldham RAA, Faber ML, Keppel TR, Buchberger AR, Waas M, Hari P, Gundry RL, Medin JA. Discovery and validation of surface <i>N</i>-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets. J Immunother Cancer. 2020 Aug;8(2). PMCID: PMC7418848

171. Koduri V, Duplaquet L, Lampson BL, Wang AC, Sabet AH, Ishoey M, Paulk J, Teng M, Harris IS, Endress JE, Liu X, Dasilva E, Paulo JA, Briggs KJ, Doench JG, Ott CJ, Zhang T, Donovan KA, Fischer ES, Gygi SP, Gray NS, Bradner J, Medin JA, Buhrlage SJ, Oser MG, Kaelin WG Jr. Targeting oncoproteins with a positive selection assay for protein degraders. Sci Adv. 2021 Feb;7(6). PMCID: PMC7864573

172. Koduri V, Duplaquet L, Lampson BL, Wang AC, Sabet AH, Ishoey M, Paulk J, Teng M, Harris IS, Endress JE, Liu X, Dasilva E, Paulo JA, Briggs KJ, Doench JG, Ott CJ, Zhang T, Donovan KA, Fischer ES, Gygi SP, Gray NS, Bradner J, Medin JA, Buhrlage SJ, Oser MG, Kaelin WG Jr. Targeting oncoproteins with a positive selection assay for protein degraders. Sci Adv. 2021 Feb;7(6). PMCID: PMC7864573

173. Khan A, Barber DL, Huang J, Rupar CA, Rip JW, Auray-Blais C, Boutin M, O'Hoski P, Gargulak K, McKillop WM, Fraser G, Wasim S, LeMoine K, Jelinski S, Chaudhry A, Prokopishyn N, Morel CF, Couban S, Duggan PR, Fowler DH, Keating A, West ML, Foley R, Medin JA. Lentivirus-mediated gene therapy for Fabry disease. Nat Commun. 2021 Feb 25;12(1):1178. PMCID: PMC7907075

174. McKillop WM, Medin JA. Molecular therapeutics in hematology: Gene therapy Molecular Hematology. 1 January 2019:319-338.

175. Rademacher MJ, Cruz A, Faber M, Oldham RAA, Wang D, Medin JA, Schloemer NJ. Sarcoma IL-12 overexpression facilitates NK cell immunomodulation. Sci Rep. 2021 Apr 15;11(1):8321. PMCID: PMC8050085

176. Domm JM, Wootton SK, Medin JA, West ML. Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing. Mol Genet Metab. 2021;134(1-2):117-131.

177. Nagree MS, Felizardo TC, Faber ML, Rybova J, Rupar CA, Foley SR, Fuller M, Fowler DH, Medin JA. Autologous, lentivirus-modified, T-rapa cell "micropharmacies" for lysosomal storage disorders. EMBO Mol Med. 2022 Apr 07;14(4):e14297. PMCID: PMC8988206

178. Rabionet M, Bernard P, Pichery M, Marsching C, Bayerle A, Dworski S, Kamani MA, Chitraju C, Gluchowski NL, Gabriel KR, Asadi A, Ebel P, Hoekstra M, Dumas S, Ntambi JM, Jacobsson A, Willecke K, Medin JA, Jonca N, Sandhoff R. Epidermal 1-O-acylceramides appear with the establishment of the water permeability barrier in mice and are produced by maturating keratinocytes. Lipids. 2022 May;57(3):183-195.

179. Zhang H, Nagree MS, Liu H, Pan X, Medin JA, Lipinski DM. rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis. Gene Ther. 2023 Apr;30(3-4):297-308.

180. Rybova J, Kuchar L, Sikora J, McKillop WM, Medin JA. Skin inflammation and impaired adipogenesis in a mouse model of acid ceramidase deficiency. J Inherit Metab Dis. 2022 Nov;45(6):1175-1190. PMCID: PMC9826362

181. Alvarez-Argote J, Dlugi TA, Sundararajan T, Kleynerman A, Faber ML, McKillop WM, Medin JA. Pathophysiological characterization of the Townes mouse model for sickle cell disease. Transl Res. 2023 Apr;254:77-91.

182. Saleh AH, Rothe M, Barber DL, McKillop WM, Fraser G, Morel CF, Schambach A, Auray-Blais C, West ML, Khan A, Fowler DH, Rupar CA, Foley R, Medin JA, Keating A. Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease. Mol Ther Methods Clin Dev. 2023 Mar 09;28:262-271. PMCID: PMC9932294

183. Domm JM, Wootton SK, Medin JA, West ML. Corrigendum to "Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing" [2021 Sep-Oct;134(1-2):117-131]. Mol Genet Metab. 2023 May;139(1):107541.

184. Kleynerman A, Rybova J, Faber ML, McKillop WM, Levade T, Medin JA. Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions. Biomolecules. 2023 Feb 01;13(2). PMCID: PMC9953133

185. Nagree MS, Rybova J, Kleynerman A, Ahrenhoerster CJ, Saville JT, Xu T, Bachochin M, McKillop WM, Lawlor MW, Pshezhetsky AV, Isaeva O, Budde MD, Fuller M, Medin JA. Spinal muscular atrophy-like phenotype in a mouse model of acid ceramidase deficiency. Commun Biol. 2023 May 25;6(1):560. PMCID: PMC10212955

186. Wang X, McKillop WM, Dlugi TA, Faber ML, Alvarez-Argote J, Chambers CB, Wilber A, Medin JA. A mass spectrometry assay for detection of endogenous and lentiviral engineered hemoglobin in cultured cells and sickle cell disease mice. J Gene Med. 2024 Jan;26(1):e3567.

187. Faber ML, Oldham RAA, Thakur A, Rademacher MJ, Kubicka E, Dlugi TA, Gifford SA, McKillop WM, Schloemer NJ, Lum LG, Medin JA. Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity. Front Immunol. 2023;14:1225610. PMCID: PMC10461807

188. Levade T, Medin JA. Acid ceramidase deficiency: Farber lipogranulomatosis and spinal muscular atrophy with progressive myoclonic epilepsy Lysosomal Storage Disorders: A Practical Guide. 22 July 2022:144-147.

189. Norris MK, Tippetts TS, Wilkerson JL, Nicholson RJ, Maschek JA, Levade T, Medin JA, Summers SA, Holland WL. Adiponectin overexpression improves metabolic abnormalities caused by acid ceramidase deficiency but does not prolong lifespan in a mouse model of Farber Disease. Mol Genet Metab Rep. 2024 Jun;39:101077. PMCID: PMC11002753

190. McKillop WM, Medin JA. Molecular therapeutics in hematology: Gene therapy Molecular Hematology. 8 March 2024:321-341.

1. Medin, J.A., Migita, M., and Karlsson, S.: Gene therapy of enzyme and immunodeficiencies in the hematopoietic system. in Cell Therapy (Morstyn, G. and Sheridan, W.P., eds.) Cambridge University Press, UK (1995).

2. Karlsson, S., Medin, J.A., Migita, M., Stahl, S.K., and Schiffmann, R.: Towards gene therapy of Gaucher's disease. in Molecular Biology of Hematopoiesis vol. 4 (Abraham, N.G. et al., eds.) Intercept Limited, Andover, United Kingdom (1996).

3. Medin JA, Karlsson S. Selection of retrovirally transduced cells to enhance the efficiency of gene therapy. Proc Assoc Am Physicians. 1997 Mar;109(2):111-9.

4. Medin JA, Karlsson S. Viral vectors for gene therapy of hematopoietic cells. Immunotechnology. 1997 Mar;3(1):3-19.

5. Medin, J.A., Richter, J. and Karlsson, S.: Clinical applications of gene therapy: Correction of genetic disease affecting hematopoietic cells. in Stem Cell Biology and Gene Therapy (Stein, G.S., Quesenberry, P., Forget, B., Weissman, S., eds.) Wiley-Liss, NY, NY (1998).

6. Medin, J.A., and Buttrick, P.: Corrective gene transfer for cardiovascular disease: Update 2000. Heart Disease. 2(6):409-421 (2000).

7. Siatskas C, Medin JA. Gene therapy for Fabry disease. J Inherit Metab Dis. 2001;24 Suppl 2:25-41; discussion 11-2.

8. Medin JA, Fowler DH. Post-transduction events in retrovirus-mediated gene therapy involving hematopoietic stem cells: beyond efficiency issues. J Cell Biochem Suppl. 2002;38:46-54.

9. Medin, J.A.: Fabry disease: vector divergence to convergence? Gene Ther. 10:1407 (2003).

10. Medin, J.A., Brenner, M., and Keating, A.: Gene therapy in blood and marrow transplantation. in Clinical Bone Marrow and Blood Stem Cell Transplantation, 3rd Edition. (Atkinson, K., Champlin, R., Ritz, J., Fibbe, W., Ljungman, P, Brenner, M., eds.) Cambridge University Press, (2004).

11. Siatskas, C., Yoshimitsu, M., and Medin, J.A.: Transduction and post-transduction events in therapy targeting hematopoietic stem cells: Focus on Fabry disease. in Progress in Stem Cell Research. (Columbus, F., ed) Nova Science Publishers, Hauppauge, NY. 191-197 (2004).

12. Stewart, A.K., and Medin, J.A.: Molecular therapeutics in haematology. in Molecular Haematology. (Provan, D., and Gribben, J., eds) Blackwell Science, Oxford, UK. 2nd Edition Ppg. 280-297 (2005).

13. Mossoba ME, Medin JA. Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials. Expert Rev Vaccines. 2006 Oct;5(5):717-32.

14. Higuchi K, Medin JA. Lentiviral vectors for gene therapy of heart disease. J Cardiol. 2007 Jan;49(1):1-11.

15. Neschadim A, McCart JA, Keating A, Medin JA. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007 Dec;13(12):1407-16.

16. Loisel-Meyer S, Foley R, Medin JA. Immuno-gene therapy approaches for cancer: from in vitro studies to clinical trials. Front Biosci. 2008 May 01;13:3202-14.

17. Symes, J., and Medin, J.A.: Genetic modification of T lymphocytes for cancer therapy. in Gene Therapy and Cancer Research Trends. (Columbus, F., ed) Nova Science Publishers, Hauppauge, NY. (2008).

18. Scaife MD, Neschadim A, Fowler DH, Medin JA. Novel application of lentiviral vectors towards treatment of graft-versus-host disease. Expert Opin Biol Ther. 2009 Jun;9(6):749-61.

19. Medin, J.A.: Molecular therapeutics in haematology: Gene Therapy. in Molecular Haematology. (Provan, D., and Gribben, J., eds) Blackwell Science, Oxford, UK. 3rd Edition Ppg. TBA (2010).

20. Levade, T., Sandhoff, K., Schulze, H., and Medin, J.A.: Chapter #143. Acid Ceramidase Deficiency: Farber Lipogranulomatosis. in Scriver’s Online Metabolic and Molecular Bases of Inherited Disease (Valle, Beaudet, Vogelstein, Kinzler, Antonarakis, Ballabio, eds). McGraw-Hill (2010).

21. Elschenbroich S, Kim Y, Medin JA, Kislinger T. Isolation of cell surface proteins for mass spectrometry-based proteomics. Expert Rev Proteomics. 2010 Feb;7(1):141-54.

22. Moretti, A., Jaffray, D.A., and Medin, J.A.: Radiation therapy and cancer treatment: From the basics to combination therapies that ignite immunity. In Experimental and Applied Immunotherapy. Edited by Jeffrey A. Medin and Daniel H. Fowler. Springer Science. (2011).

23. Ricci MJ, Medin JA, Foley RS. Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignancies. World J Stem Cells. 2014 Sep 26;6(4):380-90. PMCID: PMC4172667

24. Oldham RA, Berinstein EM, Medin JA. Lentiviral vectors in cancer immunotherapy. Immunotherapy. 2015;7(3):271-84.

25. Jones, E.E., Dworski, S., Kamani, M., Canals, D., Wada, M., Liu, X., Hannun, Y.A., Norris, J., Medin, J.A., and Drake, R.R: Detection and distribution of sphingolipids in tissue by FTICR MALDI-Imaging mass spectrometry. in Bioactive Sphingolipids in Cancer Biology and Therapy (Hannun, Luberto, Mao, Obeid, eds). Springer (2015).

26. Nagree MS, López-Vásquez L, Medin JA. Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy. World J Stem Cells. 2015 Dec 26;7(11):1233-50. PMCID: PMC4691692

27. Medin, J.A., Fowler, D.H., (Editors) Experimental and Applied Immunotherapy. Springer Science (2011).

28. Neschadim, A., Resetca, D., and Medin, J.A.: Engineering hematopoietic cells for cancer immunotherapy: Strategies to address safety and toxicity concerns. (Submitted - under revision).

29. Resetca D, Neschadim A, Medin JA. Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns. J Immunother. 2016 Sep;39(7):249-59.

30. Al-Hujaily EM, Oldham RA, Hari P, Medin JA. Development of Novel Immunotherapies for Multiple Myeloma. Int J Mol Sci. 2016 Sep 08;17(9). PMCID: PMC5037783

1. Medin, J.A., Hunt, L., Gathy, K., Evans, R.K., and Coleman, M.S.: Expression of human adenosine deaminase (ADA) in baculovirus-infected insect larvae. FASEB J. 4:A2288 (1990).

2. Medin, J.A. and Coleman, M.S.: Recombinant circle PCR (RCPCR) site-specific mutagenesis of Cys227 in human terminal deoxynucleotidyl transferase (TdT): Effect on catalytic activity. FASEB J. 5:A826 (1991).

3. Philips, A.V., Chancellor, K., Trangas,T., Medin, J.A., Yang, B.L., and Coleman, M.S.: Tissue specific transcription of the human terminal deoxynucleotidyl transferase (TdT) gene in vitro. FASEB J. 5:A1526 (1991).

4. Medin, J.A., Driggers, P.H., and Ozato, K.: 9-cis retinoic acid alters the DNA binding characteristics of recombinant RXRß. J Cell Biochem. 17A:B659 (1993).

5. Bovolenta, C., Driggers, P.H., Marks, M.S., Medin, J.A., Politis, A.D., Vogel, S.N., Coligan, J.E., and Ozato, K.: ICSBP requires an accessory molecule for high affinity DNA binding and may compete with ISGF3. J Cell Biochem. 17A:B310 (1993).

6. Segars, J., Nagata, T., Drew, P., Bours, V., Medin, J., An, J., Becker, K., Stephany, D., Siebenlist, U., and Ozato, K.: Induction of MHC Class I genes in retinoic acid treated NTera2 cells: Co-activation of retinoid receptors and P50/P65-NFkB factors. J Cell Biochem. 17A:B690 (1993).

7. Lee, I.J., Driggers, P.H., Medin, J.A., and Ozato, K.: Analysis of retinoid X receptor (RXRß) function by an in vitro transcription assay. J Cell Biochem. 17A:B653 (1993).

8. Pemrick, S.M., Sturzenbecker, L.J., Abarzna, P., Kratzeisen, C., Marks, M.S., Medin, J.A., Ozato, K., Levin, A.A., Hunziker, W., and Grippo, J.F.: 1,25-Dihydroxyvitamin D3 induction of a retinoic acid response element by a chimeric receptor. J Cell Biochem. 17A:B672 (1993).

9. Pemrick, S.M., Sturzenbecker, L.J., Kratzeisen, C., Arbuzua, P., Marks, M.S., Medin, J.A., Ozato, K., Levin, A.A., Hunziker, W., and Grippo, J.F.: Relative transactivation efficiencies of RAR and RXR chimeric receptors containing the hormone binding domain of the vitamin D receptor. Biophys J. 64(2):A278 (1993).

10. Bhaumik, D., Medin, J., Gathy, K., and Coleman, M.S.: Site-directed mutagenesis of human adenosine deaminase. Important roles for Zn, Histidine-238, and Glutamate-217 in catalysis. FASEB J. 7:A1198 (1993).

11. Nunez, S.B., Medin, J.A., Wang, K., Wahli, W., Ozato, K., and Segars, J.H.: Retinoid X receptor ß and peroxisome proliferator-activated receptor  activate the A2 estrogen response element. in Collected Abstracts of: The Endocrine Soc Ann Mtg. p54 (1993).

12. Minucci, S., Hallenbeck, P., Medin, J.A., Zand, D.J., Nikodem, V., and Ozato, K.: RXR and diverse heterodimer partners are involved in RA-mediated transcription in embryonal carcinoma cells. J Cell Biochem. 18A:K222 (1994).

13. Nunez, S.B., Keller, H., Medin, J., Ozato, K., Wahli, W., and Segars, J.: Evidence for dominant negative inhibition of PPAR-mediated ERE activation by RXRß deletion mutants. J Cell Biochem. 18A:K223 (1994).

14. Blanco, J., Segars, J., Medin, J., Minucci, S., and Ozato, K.: C-terminal truncation of RXRß inhibits retinoic acid induced transcription in embryonal carcinoma cells. J Cell Biochem. 18C:L204 (1994).

15. Schiffmann, R., Medin, J.A., Ward, J., Stahl, S., Cottler-Fox, M., and Karlsson, S.: Transfer of the human glucocerebrosidase (hGC) gene into hematopoietic stem cells of non-ablated mice. Blood. 84(supp1):401a (1994).

16. Medin, J.A., Migita, M., M., Pawliuk, R., Jacobson, S., Amiri, M., Humphries, R.K., and Karlsson, S.: Correction of the metabolic deficiency in Gaucher's disease using a bicistronic retroviral vector that allows selection of transduced cells. Blood. 84(suppl1):356a (1994).

17. Migita, M., Medin, J.A., Pawliuk, R., Jacobson, S., Amiri, M., Humphries, R.K., and Karlsson, S.: The enzyme deficiency in Gaucher fibroblasts is corrected by retroviral vectors containing the genes for the glucocerebrosidase gene and the selectable cell surface antigen, CD24. Blood. 84(suppl1):357a (1994).

18. Medin, J.A., Migita, M., Jacobson, S., Pawliuk, R., Humphries, R.K., and Karlsson, S.: Sorting of hematopoietic cells transduced with a retroviral vector that delivers a therapeutic gene and a cell surface marker. J Invest Med. 43 (suppl.2):278A (1995).

19. Medin, J.A., Migita, M., Pawliuk, R., Jacobson, S., Amiri, M., Kluepfel-Stahl, S., Brady, R.O., Humphries, R.K. and Karlsson, S.: A bicistronic therapeutic retroviral vector enables sorting of transduced CD34+ cells and corrects the enzyme deficiency in cells from Gaucher patients. Blood. 86(suppl1):413a (1995).

20. Migita, M., Medin, J.A., Pawliuk, R., Anderson, S., Stahl, S.K., Amiri, M., Humphries, R.K., and Karlsson, S.: Selection and enzymatic correction of transduced cells from Gaucher patients using bicistronic vectors containing genes for glucocerebrosidase and the selectable cell surface antigen, CD24. Blood. 86(suppl1):626a (1995).

21. Migita, M., Amiri, M., Medin, J.A., Nagle, J.W., and Karlsson, S.: The level of enzyme activity generated by two different glucocerebrosidase cDNAs following gene transfer varies widely. Blood. 86(suppl1):1003a (1995).

22. Nunez, S.B., Medin, J.A., and Segars, J.H.: Pattern of RXR/PPAR heterodimerization binding to the ERE compared to the estrogen-receptor binding. Pediat Res. 37(4):A95 (1995).

23. Medin, J.A., Pawliuk, R., Amiri, M., Brooks, C., Kluepfel-Stahl, Migita, M., Humphries, R.K., and Karlsson, S.: Selection and metabolic correction of normal and Gaucher patient CD34+ hematopoietic progenitors with a therapeutic and selectable retrovirus. J Invest Med. 44(3):279A (1996).

24. Pemrick, S.M., Arbuzua, P., Kratzeisen, C., Sturzenbecker, L.J., Levin, A.A., Hunziker, W., Marks, M.S., Medin, J.A., Ozato, K., and Grippo, J.F.: Functional comparison of retinoic acid receptors with heterologous ligand-binding domains. Biophys J. 70(2):U483 (1996).

25. Medin, J.A., Tudor, M., Simovitch, R., Quirk, J.M., Jacobson, S., Murray, G.J., and Brady, R.O.: Gene therapy for Fabry disease: Expression, secretion, and uptake of -galactosidase A driven by a high-titer recombinant retroviral vector. FASEB J. 10(6):A1152 (1996).

26. Nunez, S.B., Medin, J.A., Wahli, W., and Segars, J.: Mechanism of estrogen-responsive gene activation by the retinoid X receptor and peroxisome proliferator-activated receptor. in Collected Abstracts of: The Endocrine Soc Ann Mtg. p54 (1996).

27. Migita, M., Anderson, S., Stahl, S.K., Medin, J.A., Humphries, R.K., and Karlsson, S.: Selection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients using bicistronic vectors containing the genes for glucocerebrosidase and the selectable cell surface antigen, CD24. in Collected Abstracts of: Japan Soc of Gene Ther. (1996).

28. Tudor, M., Brady, R.O., and Medin, J.A.: Correction of the metabolic defect in Fabry disease patient cells through gene transfer. Proc Soc for Exp Biol and Med. 212(4):388 (1996).

29. Takenaka, T. Hendrickson, C.S., Tudor, M., Schiffmann, R., Brady, R.O., and Medin, J.A.: Extending metabolic cooperativity in gene transfer for Fabry disease: Transduction of patient bone marrow cells leads to intracellular enzymatic correction and secretion. FASEB J. 11(9):A1090 (1997).

30. Takenaka, T., Tworek, D., Brady, R.O., and Medin, J.A.: Direct biochemical evidence for circulating -galactosidase A derived from transduced bone marrow cells. in Collected Abstracts of: The American Society of Gene Therapy 1st Annual Meeting (1998).

31. Medin, J.A., Brandt, J.E., Li, C., Rosler, E., Fitting, P., Chute, J., and Hoffman, R.: Genetic modification and expansion of human CD34+CD38- cells. in Collected Abstracts of: 2nd Conference on Stem Cell Gene Therapy (1998).

32. Brandt, J.E., Medin, J.A., Rosler, E.S., Li, C., Chute, J.P., and Hoffman, R.: High-level transgene expression by human CD34+CD38- hematopoietic stem cells following in vitro expansion. Exp Hematol. 26: 640 (1998).

33. Brandt, J.E., Medin, J.A., Rosler, E.S., Nelson, M.C., Chute, J.P., and Hoffman, R.: Retroviral gene marking of human and non-human primate bone marrow progenitor and stem cells. AFMR. (1998).

34. Takenaka, T., Oshima, T., Tworek, D.M., Murray, G.J., Quirk, J.M., Brady, R.O., Kulkarni, A.B., and Medin, J.A.: Long-term retroviral-mediated correction in -galactosidase A deficient mice. Blood. 92 (suppl1):298a (1998).

35. Karp, B.I., Ali, S., Takenaka, T., Brady, R.O., and Medin, J.A.: Modification of the human -galactosidase A (-gal A) C-terminus enhances uptake by Fabry patient fibroblasts. FASEB J. 13:A1403 (1999).

36. Medin, J.A., Brandt, J.E., Rosler, E., Li, C., Kelley, L., Chute, J., and Hoffman, R.: Expansion of genetically modified human CD34+ cells with maintenance of phenotype and extended expression of the transgene. The American Society of Gene Therapy 2nd Annual Meeting. (1999).

37. Medin, J.A., Brandt, J.E., Rosler, E., Li, C., Kelley, L., Chute, J., and Hoffman, R.: Expansion of genetically modified human CD34+ cells with maintenance of phenotype and extended expression of the transgene. Exp Hematol. 27: 62 (1999).

38. Deans, R., Kowalski, R., Buyaner, D., Slawecki, M., Qin, G., Lee, K., Mosca, J., Moseley, A., Hoffman, R., and Medin, J.A.: Fabry’s disease: A clinical application of gene transfer into mesenchymal stem cells. Blood. 94(suppl2):418b (1999).

39. Siatskas, C., Hu, Z., Westbrook, C., and Medin, J.A.: Identification and characterization of a novel c-kit splice variant: implications for the onset and development of cellular transformation. Blood. 94(suppl2):143b (1999).

40. Takenaka, T., Murray, G., Qin, G., Quirk, J., Ohshima, T., Clark, K., Qasba, P., Brady, R.O., Kulkarni, A., and Medin, J.A.: Long-term enzyme expression and lipid reduction in multiple organs of -gal A deficient mice receiving transduced bone marrow cells. Blood. 94(suppl1):642a (1999).

41. Keralavarma, B., Qin, G., Kelley, L., Reddy, D., Devine, S., and Medin, J.A.: Improved “suicide” retroviral vector containing mutant HSV-tk gene confers increased sensitivity to gancyclovir. Blood. 94(suppl2):329b (1999).

42. Qin, G., Clark, K., Kelley, L., Keralavarma, B., Mulder, C., and Medin, J.A.: Development of preselective gene therapy for Fabry disease. Keystone Symposia-Gene Therapy: The Next Millenium. p.87 (2000).

43. Qin, G., Clark, K., Kelley, L., Mulder, C., Turin, J., Keralavarma, B., Chung, T., and Medin, J.A.: Development of preselective gene therapy for Fabry disease. Mol Ther. 1:S73 (2000).

44. Medin, J.A.: Enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving retrovirally-transduced bone marrow cells. Joint meeting of: Int’l. Symp. on Innovative Therapies & 6th Int’l Symp. on Mucopolysaccharidosis and Related Diseases. (2000).

45. Siatskas, C., Hu, Z., Westbrook, C., and Medin, J.A.: Identification and characterization of a novel c-kit splice variant. 13th Int’l. Symp. on Treatment of Leukemia and Cancer. (2000).

46. Qin, G., Clark, K., Telsh, K., Kelley, L., Malech, H., Turin, J., Takenaka, T., Howard, T., Chung, T., Howard, B., Brady, R.O., and Medin, J.A.: Long-term improvement in a gene therapy outcome for Fabry disease by employment of a preselective strategy. Cancer and Molecular Genetics in the 21st Century (2000).

47. Siatskas, C., Hu, Z., Westbrook, C., and Medin, J.A.: Identification of a novel alternatively spliced c-kit variant. Cancer and Molecular Genetics in the 21st Century (2000).

48. Qin, G., Kelley, L., Peace, D., and Medin, J.A.: Retrovirus-mediated gene transfer of prostate specific antigen (PSA) into dendritic cell precursors for the immunotherapy of prostate cancer. Cancer Gene Ther. 7:S27 (2000).

49. Peace, D., Qin, G., Kelley, L., and Medin, J.A.: Immunogene therapy for prostate cancer by engineered expression of prostate specific membrane antigen (PSMA). Cancer Gene Ther. 7:S29 (2000).

50. Smith, S.L., Siatskas, C., Agbemadzo, B., Kiss, J., Medin, J.A., and Moldwin, R.L.: Long-term culture of enGFP+ cells in cord blood after retroviral transduction and culture with TPO, FLT-3L, SCF, and VEGF. Blood. 96(suppl1):773a (2000).

51. Hendricks, J.K., Buyaner, D., Liu, L., Lee, K., Medin, J.A., Murray, G.J., Brady, R.O., and Deans, R.: Use of human mesenchymal stem cells as gene delivery vehicles for the treatment of Fabry’s disease. Blood. 96(suppl1):845a (2000).

52. Siatskas, C., Qin, G., Smith, S.L., Moldwin, R.L., Brady, R.O., and Medin, J.A.: Enrichment and functional assessment of -gal A-transduced murine and human primitive hematopoietic cells: Implications for the treatment of Fabry disease. Mol Ther. 3:S222 (2001).

53. Medin, J.A., Qin, G., Hou, J., Kelley, L., Peace, D., and Fowler, D.: Dendritic cells engineered to express prostate-specific antigens for immunotherapy of prostate cancer. Exp Hematol. 29(suppl1):55 (2001).

54. Li, J.-H., Shi W., Chia, M., Medin, J., Huang, D., Klamut, H.J., Yeh, W.-C., Richardson, C., and Liu, F.-F.: A novel EBV-targeted adenoviral vector utilizing a non-cleavable FasL for nasopharyngeal cancer therapy. Cancer Gene Ther. 8:035 (2001).

55. Medin, J.A., Liang, S.-B., Qin, G., Hou, J. and Fowler, D.: Retrovirally-transduced dendritic cell vaccines boost immunity to prostate antigen-expressing murine tumors. Blood. 98: 2915 (2001).

56. Liang, S.-B., Hou, J.W.-S., Peace, D.J., Fowler, D.H., and Medin, J.A.: Vaccination with retrovirally-transduced dendritic cells introduces cellular and humoral immune responses along with specific protection against prostate antigen expressing tumors. Cancer Gene Ther. 10:S34 (2003).

57. Mossoba, M.E., Siatskas, C., and Medin, J.A.: Development of cancer immunotherapy using Her2/neu-transduced dendritic cells. Keystone Symposia: Dendritic cells (J7) p.65 (2003).

58. Yoshimitsu, M., Siatskas, C., Liang, S.-B., Eliopoulos, N., Galipeau, J., and Medin, J.A.: Gene therapy for Fabry disease by lentiviral transduction of primitive hematopoietic cells and stroma cells. European Society of Gene Therapy Meeting, Edinburgh, Scotland (2003).

59. Siatskas, C., and Medin, J.A.: Pharmacological activation of KDR induces the selective proliferation of lentivirally-transduced cells. European Society of Gene Therapy Meeting, Edinburgh, Scotland (2003).

60. Du Manoir, J.M., Viloria-Petit, A., Man, S., Mossoba, M., Medin, J.A., and Kerbel, R.S.: Antitumor effects of low-dose metronomic cyclophosphamide combined with Herceptin in orthotopic erbB2-overexpressing mammary tumors. Clinical Cancer Research. 9(16):6149S-6149S Part 2 Suppl. (2003).

61. Yoshimitsu, M., Tao, K., Fan, X., West, L., and Medin, J.A.: Sustained therapeutic levels of -galactosidase A in Fabry mice by neonatal gene therapy. Glycoproteinoses: An International Workshop on Advances in Pathogenesis and Therapy. (2004).

62. Yoshimitsu, M., Tao, K., Fan, X., West, L., and Medin, J.A.: Neonatal gene therapy with a lentiviral vector results in therapeutic levels of -galactosidase A correction in Fabry mice. Molecular Therapy. 9(Suppl.1):S327 (2004).

63. Ramsubir, S.H., Tardy, C., Carpentier, S., Levade, T. and Medin, J.A.: Enhancement of gene therapy approaches for the correction of Farber disease. Molecular Therapy. 9(Suppl.1):S330 (2004).

64. Bielawski, J.C., Fowler, D., and Medin, J.A.: FasL-over-expressing T lymphocytes as effector cells in anti-prostate cancer gene therapy. Molecular Therapy. 9(Suppl.1):S364 (2004).

65. Ayach, B., Yoshimitsu, M., Rasaiah, V.I., Siatskas, C., Lee, P., Lim, H., Dawood, F., Chen, M., Medin, J.A., and Liu, P.: c-kit receptor is essential for functional cardiac repair post-MI. J Cardiac Failure. 10: S24 (2004).

66. Ayach, B., Siatskas, C., Yoshimitsu, M., Lee, P., Lim, H., Dawood, F., Chen, M., Medin, J.A., and Liu, P.: c-kit + BM cells are essential for reducing deteriorating myocardial and heart function post-myocardial infarction. Circulation. 110: III-68 (2004).

67. Yoshimitsu, M., Tao, K., Sato, T., Murray, G.J., West, L., Brady, R.O., and Medin, J.A.: Long-term expression of human -galactosidase A in Fabry mice by neonatal lentiviral gene transfer. American Society for Human Genetics. (2004).

68. Ayach, B., Yoshimitsu, M., Rasaiah, V.I., Siatskas, C., Lee, P., Lim, H., Dawood, F., Chen, M., Medin, J.A., and Liu, P.: c-kit receptor is essential for functional cardiac repair post-MI. Canadian Journal of Cardiology. 20: 110D (2004).

69. Sato, T., Yoshimitsu, M., Tao, K., West, L., and Medin, J.A.: Bioluminescent imaging of a marking transgene product in mice resulting from neonatal injection of recombinant lentiviral vector. Third Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases. (2004).

70. Ayach, B., Yoshimitsu, M., Dawood, F., Arab, S., Sun, M., Chan, M.Y., Higuchi, K., Stanford, W.L., Medin, J.A., Liu, P.P.: Stem cell factor receptor induces progenitor and natural killer cell mediated cardiac survival and repair post-myocardial infarction J Cardiac Failure. 11:S91 (2005).

71. Ayach, B., Dawood, F., Chan, M.Y., Higuchi, K., Medin, J.A., Stanford, W.L., Liu, P.P.: CXCR4 receptor improves cardiac remodelling and revascularization post-MI. J Cardiac Failure. 11:S126 (2005).

72. Surzyn, M., Bielawski, J., Medin, J.A., and Sefton, M.: Non-destructive method for in vivo assessment of microencapsulated cell viability. Society for Biomaterials 30th Annual Meeting. (2005).

73. Sato, T., Neschadim, A., Rasaiah, V.I., Konrad, M., Lavie, A., and Medin, J.A.: Development of a novel lentivirus-based suicide gene therapy approach using modified human thymidylate monophosphate kinase. Japanese Society of Gene Therapy 11th Annual Meeting. (2005).

74. Ayach, B., Yoshimitsu, M., Dawood, F., Sun, M., Arab, S., Chen, M., Zhang, J., Higuchi, K., Stanford, W.L., Medin, J.A., and Liu, P.P.: Stem cell factor receptor induces progenitor and natural killer cell mediated cardiac survival and repair post-myocardial infarction. Circulation. 112:II-266 (2005).

75. Ayach, B., Dawood, F., Chen, M., Higuchi, K., Medin, J.A., Stanford, W.L., and Liu, P.P.: Cxcr4 receptor improves cardiac remodeling and revascularization post-myocardial infarction. Circulation. 112:II-37 (2005).

76. Yoshimitsu, M., Siatskas, C., Liang, S.-B., Rasaiah, V.I., Poeppl, A.G., Higuchi, K., Ramsubir, S., Takenaka, T., Murray, G.J., Tei, C., Brady, R.O., and Medin, J.A.: Long-term and sustained correction in hearts of Fabry mice receiving lentivirally transduced hematopoietic stem/progenitor cells. Circulation. 112:II-11 (2005).

77. Medin, J.A., Liang, S.-B., Poeppl, A., Yoshimitsu, M., Walia, J.S., Cai, J., Rasaiah, V.I., and Fowler, D.H.: Functional engraftment of retrovirally transduced and pre-selected hematopoietic cells into partially ablated recipient Fabry mice. Blood. 106:847a (2005).

78. Sato, T., Neschadim, A., Rasaiah, V.I., Konrad, Fowler, D.H., M., Lavie, A., and Medin, J.A.: Improved suicide gene therapy: lentiviral gene transfer of equine herpes virus type 4 thymidine kinase into target cells. Blood. 106:396b (2005).

79. Sato, T., Neschadim, A., Rasaiah, V.I., Konrad, Lavie, A., and Medin, J.A.:. Development of a novel lentivirus-based suicide gene therapy approach using modified human thymidylate monophosphate kinase. Blood. 106:397b (2005).

80. Yoshimitsu, M., Siatskas, C., Liang, S.-B., Rasaiah, V.I., Higuchi, K., Murray, G.J., Takenaka, T., Tei, C., Brady, R.O., and Medin, J.A.: Long-term and sustained correction of the alpha-galactosidase A deficiency in Fabry mice and patient cells receiving lentivirally transduced hematopoietic stem/progenitor cells. Blood. 106:374a (2005).

81. Walia, J.S., Cai, J.H., Fowler, D.H., and Medin, J.A.: Genetically modified DCs engineered to express PSA and/or PSMA can induce a potent immune response against prostate cancer cells. Blood. 106:860a (2005).

82. Walia, J.S., Yoshimitsu, M., Silvertown, J.D., Poeppl, A.G., Rasaiah, V.I., Donahue, R.E., Andrews, R.G., McCart, J.A., and Medin, J.A.: Initiation of a pre-clinical gene therapy study in non-human primates using lentivectors targeting hematopoietic cells for correction of Fabry disease. Blood. 106:474b (2005).

83. Lund, N., Lingwood, C.A., Medin, J.A., Olsson, M.L., Levene, C., Yahalom, V., and Branch, D.R.: Novel mechanisms for Pk (Gb3) inhibition of HIV infection. Blood. 106:413a (2005).

84. Silvertown, J., Walia, J.S., Summerlee, A.J., and Medin, J.A.: Functional expression of mouse relaxin-1 (M1) and Relaxin-3 (M3) in the lung from an Ebola pseudotyped lentivirus via tracheal delivery. The Endocrine Society Annual Meeting. OR41-1 (2006).

85. Silvertown, J., Symes, J.C., Nonaka, T., Fleshner, N., Summerlee, A.J.S., and Medin, J.A.: H2 Relaxin analog suppresses prostate tumor growth. The Endocrine Society Annual Meeting. P3-351 (2006).

86. Sato, T., Neschadim, A., Rasaiah, V.I., Konrad, M., Lavie, A., and Medin, J.A.: Development of a novel lentivirus-based suicide gene therapy approach using modified human thymidylate monophosphate kinase. Journal of Gene Medicine. 8:399 (2006).

87. Higuchi, K., Ayach, B., Dawood, F., Chen, M., Bansal, T., Liu, P.P., and Medin, J.A.: Overexpression of Kit Ligand-2 by direct cardiac injection of recombinant lentiviruses improves cardiac repair and rescues mice post-myocardial infarction. American Heart Association Annual Meeting. (2006).

88. Ayach, B.B., Higuchi, K., Bansal, T., Dawood, F., Lam, K., Chen, M., Tata, N., Stanford, W.L., Medin, J.A., and Liu, P.P.: CXCR4 improves cardiac remodeling and neovascularization, and regulated inflammatory and progenitor stem cell mobilization post-myocardial infarction. American Heart Association Annual Meeting. (2006).

89. Ayach, B.B., Dawood, F., Higuchi, K., Lam, K., Bansal, T., Chen, M., Medin, J.A., Stanford, W.L., and Liu, P.P.: SCF/C-kit compensates for FL/FLT3 deficiency to mediate mycardial rescue and repair post-MI. American Heart Association Annual Meeting. (2006).

90. Maekawa, Y., Ayach, B.B., Dawood, F., Chen, M., Higuchi, K., Medin, J.A., and Liu, P.P.: MRL mice are protected against rupture post myocardial infarction through unique matrix dynamics. American Heart Association Annual Meeting. (2006)

91. Ayach, B.B., Lam, K., Higuchi, K., Dawood, F., Stanford, W.L., Medin, J.A., and Liu, P.P.: C-kit receptor regulates cell mobilization and cytokine production post-myocardial infarction. Canadian Cardiovascular Society Annual Meeting. (2006).

92. Ayach, B.B., Dawood, F., Higuchi, K., Lam, K., Bansal, T., Chen, M., Medin, J.A., Stanford, W.L., and Liu, P.P.: SCF/C-kit compensates for FL/FLT3 deficiency to mediate mycardial rescue and repair post-MI. Canadian Cardiovascular Society Annual Meeting. (2006).

93. Ayach, B.B., Higuchi, K., Bansal, T., Dawood, F., Lam, K., Chen, M., Tata, N., Stanford, W.L., Medin, J.A., and Liu, P.P.: CXCR4 improves cardiac remodeling and neovascularization, and regulated inflammatory and progenitor stem cell mobilization post-myocardial infarction. Canadian Cardiovascular Society Annual Meeting. (2006).

94. Neschadim, A., Sato, T., Fowler, D.H., Lavie, A., and Medin, J.A.: Development of improved lentiviral ‘suicide’ gene therapy for the management of GvHD in allogeneic BMT. Blood. 108: 929a (2006).

95. Mossoba, M.E., Walia, J.S., Rasaiah, V.I., Fowler, D.H., and Medin, J.A.: Overcoming self-tolerance: Long-term protection against specific erbB2-expressing prostate tumors using low doses of lentivirus-transduced DCs. Blood. 108: 1056a (2006).

96. Sato, T., Sukegawa, J., Medin, J., Yanagisawa, T.: A model for mitochondrial myopathy; AZT-triphosphate toxicity. J Pharmacol Sciences. 103:72P (2007).

97. Medin, J.A., Mossoba, M.E., Walia, J.S., Rasaiah, V.I., Foley, J.E., Buxhoeveden, N., and Fowler, D.H.: Low doses of lentivirus-transduced DCs overcome self-tolerance and protect against ErbB2-expressing prostate tumors. IMPaCT: Innovative Minds in Prostate Cancer Today. DODPCRP Meeting. Atlanta, Georgia. (2007).

98. Ayach, B.B., Higuchi, K., Dawood, F., Lam, K., Chen, M., Tata, N., Stewart, D.J., Stanford, W.L., Medin, J. A., and Liu, P.P.: CXCR4 synergistically activates FLT3 receptor and regulates mobilization of innate immune and stem progenitor cells post-myocardial infarction. Canadian Journal of Cardiology. 23:159C (2007).

99. Higuchi, K, Yoshimitsu, M., Takenaka, T., Medin, J.A., and Tei, C.: Enzymatic correction in hearts of Fabry mice by neonatal injection of a recombinant lentiviral vector that engineers expression of alpha-galactosidase A. J American College of Cardiology. 51:page? (2008).

100. Sato, T., Neschadim, A., Sukegawa, J., Yanagisawa, T., and Medin, J.A.: Bystander killing highlights the utility of the tmpkF105Y/AZT system for suicide gene therapy of cancer. Molecular Therapy. 16:S158 (2008).

101. Devine, S.P., Neschadim, A., Fowler, D.H., Lavie, A., and Medin, J.A.: Towards a master cell fate control lentiviral vector for cell and gene therapy. Molecular Therapy. 16:S211 (2008).

102. Neschadim, A., Lavie, A., Sato, T., Fowler, D.H., and Medin, J.A.: Novel lentiviral cell fate control gene therapy based on engineered variants of the human deoxycytidine kinase. Molecular Therapy. 16:S212 (2008).

103. Amarnath, S., Foley, J., Mariotti, J., Costanzo, C., Ryan, K., Levine, B., Dropulic, B., Medin, J.A., and Fowler, D.: Incorporation of the tmpk/AZT cell fate safety switch in human Th2Rapamycin cells for allograft augmentation after hematopoietic stem cell transplantation. Molecular Therapy. 16:S237 (2008).

104. Walia, J.S., Neschadim, A., Ramsubir, S., Yoshimitsu, M., Head, R., Rasaiah, V.I., Donahue, R.E., Cheung, F., Jaffray, D., McCart, J.A., and Medin, J.A.: Acid ceramidase expression at supranormal levels in non-human primates following autologous transplantation of lentivirus-transduced hematopoietic cells. Molecular Therapy. 16:S263 (2008).

105. Head, R., Turner, P.V., Madden, M., Baig, E., Tang, N., Lafrance, S., Belford, S., Walia, J., Moloo, B., Medin, J.A., and McCart, J.A.: Assessment of vaccinia virus toxicity after intraperitoneal delivery to rhesus macaques. Molecular Therapy. 16:S272 (2008).

106. Siegers, G.M., Al-Beirouti, B.M., Mathieson, A.M., Felizardo, T.C., Helke, S., Medin, J.A., and Keating, A.: Gamma delta T cells (GDTCs) to eliminate minimal residual disease (MRD) in Chronic Myeloid Leukemia (CML): A pre-clinical model. Blood. 112: 574 (2008).

107. Medin, J., Walia, J., Neschadim, A., Fan, X., Madden, M., Cheung, F., Jaffray, D., Levade, T., Brady, R., and McCart, J.A. Outcomes of testing lentivector-mediated gene therapy for Farber disease in non-human primates. Molec Genet Metabol. 96:S31 (2009).

108. Maekawa, Y., Mizue, N., Chan, A.N., Shi, Y., Liu, Y., Manyin, C., Dawood, F., de Couto, G., Li, G.H., Medin, J.A., and Liu, P.P.: Survival and cardiac remodeling after myocardial infarction are critically dependent on the host innate immune Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) signaling: A regulator of bone marrow-derived dendritic cells. J Card Fail. 15(6):S1 (2009).

109. Hirayama, S., Sato, M., Zehong, G., Liu, M., Waddell, T.K., Medin, J.A., and Keshavjee, S.: Lentivirus-mediated long-term gene transduction in the lung attenuates allograft airway obliteration after mouse intra-pulmonary trachea transplantation. (submitted)

110. Pacienza, N., Mizue, N., Yoshimitsu, M., Scaife, M., Foley, R., and Medin, J.A.: Generation and implementation of a novel murine xenograft model for evaluating human hematopoietic cell-targeted gene therapies for Fabry disease. Blood. 114(22):1385-1386 (2009).

111. Pacienza, N., Mizue, N., Scaife, M., Foley, R., and Medin, J.A.: Use of MGMT resistance to enrich for transduced hematopoietic cells in gene therapy for Fabry disease. Blood. 114(22):1388 (2009).

112. Likar, Y., Zurita, J., Dobrenkov, K., Shenker, L., Neschadim, A., Medin, J.A., James, L., Cai, S., Hricak, H., and Ponomarev, V.: A new pyrimidine-specific human-derived reporter gene for PET imaging in humans: Truncated mutant deoxycytidine kinase. World Molecular Imaging Congress. Sept. 25 2009.

113. Amarnath, S., Wang, J., Massey, P.R., Riley, J.L., Levine, B., June, C.H., Medin, J.A., and Fowler, D.: PD-L1 Immuno-gene therapy under cell fate control: Persistence of cellular delivery vehicle and transgene expression. Blood. 114(22):1387 (2009).

114. Wang, A.Y., Crome, S.Q., Jenkins, K.M., Medin, J.A., Bramson, J.L., and Levings, M.K.: Interaction between adenoviral vector-transduced dendritic cell-based cancer vaccine and T regulatory or T helper 17 cells. Mol Ther. 18:S31 (2010).

115. ) Likar, Y., Zurita, J., Shenker, L., Moroz, M., Cai, S., Neschadim, A., Medin J., Hricak, H., Sadelain, M., and Ponomarev, V.: A new human-derived reporter gene suitable for clinical PET imaging of T-cell trafficking. Mol Ther. 18:S71 (2010).

116. Neschadim, A., Lavie, A., Sato, T., Fowler, D.H., Ponomarev, V., and Medin, J.A.: Next-generation lentiviral cell fate control gene therapy based on engineered variants of human deoxycytidine kinase. Mol Ther. 18:S129 (2010).

117. Amarnath, S., Wang, J., Mangus, C., Riley, J., Levine, B., June, C., Medin, J., and Fowler, D.: Engineered human regulatory T cells expressing lentiviral PDL1 under cell fate control prevent lethal xenogeneic GVHD. Mol Ther. 18:S132 (2010).

118. Sato, T., Neschadim, A., Sukegawa, J., Yanagisawa, T., and Medin, J.A.: Mechanisms of the tmpk/AZT-system bystander effect; cell fate control gene therapy for anti-cancer treatment. Mol Ther. 18:S196 (2010).

119. Scaife, M.D., Devine, S.P., Neschadim, A., Pacienza, N.A., Fowler, D.H., and Medin, J.A.: Truncated CD19 fused with mutant human tmpk: A versatile cell fate control safety cassette. Mol Ther. 18:S196 (2010).

120. Mossoba, M., Foley, J., Gangopadhyay, A., Ylaya, K., Winterton, M., Taylor, J., Massey, P., Hewitt, S.M., Medin, J.A., and Fowler, D.H.: Effective dendritic cell immuno-gene therapy of established ErbB2-expressing tumors using pentostatin-based host immune depletion and subsequent host Th1/Tc1 cell transfer. Mol Ther. 18:S257 (2010).

121. Scaife, M.D., Devine, S.P., Neschadim, A., Pacienza, N.A., and Medin, J.A.: Lentiviral vector correction of Fabry disease encompassing a cell fate control safety element. Mol Ther. 18:S300 (2010).

122. Hirayama, S., Sato, M., Zehong, G., Liu, M., Waddell, T.K., Medin, J.A., and Keshavjee, S.: Lentivirus-mediated long-term gene transduction in the lung attenuates allograft airway obliteration after mouse intra-pulmonary trachea transplantation. J Heart Lung Transpl. 29:S117 (2010).

123. Sato, T., Ramsubir, S., Higuchi, K., Medin, J., Yanagisawa, T.: VEGF increases lentivector distribution after neonatal injection. J. Pharm. Sciences. 112:128P (2010).

124. Medin, J.: Hematopoietic cell-based gene therapy for Fabry disease and Farber disease. XXXIII World Congress of the International Society of Hematology (2010).

125. Lavie, A., Fowler, D., and Medin, J.: Development and implementation of novel cell fate control systems for cell therapy and GvHD. XXXIII World Congress of the International Society of Hematology (2010).

126. Sato, T., Neschadim, A., Medin, J.A., and Yanagisawa, T.: Gap junction-mediated bystander killing highlights the utility of the tmpk/AZT system for cancer suicide gene therapy. J Gene Med. 12:1052-1053 (2010).

127. Medin, J., Pacienza, N., Mizue, N., Fan, X., Scaife, M.: Enhanced Gb3 reduction mediated by lentivector transduction of human CD34+ bone marrow-derived cells in a novel Fabry/NOD/SCID xenograft model. Molec Genet Metabol. 102:S29 (2011).

128. Pacienza, N., Mizue, N., Scaife, M, and Medin, J.: MGMT-based selection of lentivector transduced cells: Application to Fabry disease. Molec Genet Metabol. 102:S32 (2011).

129. Filomeno, P.A., Dayan, V., Kandel, R.A., Wang, X.-H., Felizardo, T.C., Jelveh, S., Filomeno, A., Medin, J. A., Keating, A., and Ferguson, P.C.: Human bone marrow mesenchymal stromal cells (MSCs) decrease proliferation of human soft tissue sarcoma (STS) cell lines in vitro and do not affect local recurrence in xenograft models in vivo. ORS 2011 Meeting

130. Alayoubi, A., Wang, J.C.M., Au, B.C.Y., Carpentier, S., Garcia, V., Dworski, S., Turner, P., El-Ghamrsni, S., Hakem, R., Levade, T., and Medin, J.A.: Generation and correction of a novel mouse model of acid ceramidase deficiency. Mol Ther 20:S123 (2012).

131. Au, B.C.Y., Lee, C.-Y., Lopez-Perez, O., Fan, X., Foltz, W., Madden, M., Goldstein, A., van der Kwast, T., McCart, J.A., and Medin, J.A.: Prostate cancer immunotherapy by direct lentivirus vector injection: murine and rhesus macaque models. Mol Ther 20:S260 (2012).

132. Dworski, S., Berger, A., Yoshimitsu, M., Alayoubi, A., Au, B., Exertier, M., Forster, J., Furlonger, C., Wang, J.C., Takenka, T., Paige, C.J., and Medin, J.A.: Systemic ceramide accumulation causes dysregulated hematopoiesis. Blood 120:21 November (2012).

133. Alayoubi, A., Wang, J.C.M., Au, B.C.Y., Carpentier, S., Garcia, V., Dworski, S., Turner, P., El-Ghamrsni, S., Hakem, R., Levade, T., and Medin, J.A.: Generation and correction of a novel mouse model of acid ceramidase deficiency. Mol Ther 20(Suppl. 1):S123-S123 (2012).

134. Au, B.C.Y., Lee, C.J., Lopez-Perez, O., Fan, X., Foltz, W., Madden, M., Goldstein, A., van der Kwast, T., McCart, J.A., and Medin, J.A.: Prostate cancer immunotherapy by direct lentivirus vector injection: murine and rhesus macaque models. Mol Ther 20(Suppl. 1):S260-S261 (2012).

135. Dworski, S., Jones, E., Alayoubi, A., Medin, J.A., and Drake, R.: Identification of accumulated ceramide species in a Farber disease mouse model by MALDI-MS imaging. 2013 ASMS (American Society for Mass Spectrometry), February (2013).

136. Auray-Blais, C., Boutin, M., Lavoie, P., Casey, R., Clarke J.T.R., Foley, S.R., Keating, A., Khan, A., West, M.L., and Medin, J.A.: Gene therapy for Fabry disease patients: the importance of efficient biomarker monitoring. Molec Genet and Metabol. 108:S21 (2013).

137. Dworksi, S., Berger, A., Yoshimitsu, M., Alayoubi, A., Au, B., Forster, J., Furlonger, C., Wang, J.C.M., Takenaka, T., Paige, C.J., and Medin, J.A.: Hematopoiesis is dysregulated in a novel mouse model of Farber disease. Molec Genet and Metabol., 108:S36 (2013).

138. Khan, A., Au, B.C., Tailor, C., Rothe, M., Bischof, D., Sirrs, S., Auray-Blais, C., Rupar T., Prokopishyn, N., Ohoski, P., Huang, J., Paul, G., Benabid, R., Viswanathan, S., Morel, C., Raiman, J., Schambach, A., West, M., Keating, A., Cornetta, K., Foley, R., and Medin, J.A.: Pre-clinical patient cell mobilizations and transduction outcomes in preparation for a Clinical Trial Application of lentivirus-mediated gene therapy for Fabry disease. ASGCT 17TH Annual Meeting May (2014)

139. Au, B.C., Hermann, F., Rana, N., Neschadim, A., Huss, R., Guenther, C., and Medin, J.A.: Bystander tumor cell killing mediated by gap junctions formed with MSCs engineered to express novel prodrug-converting enzymes. ASGCT 17th Annual Meeting May (2014).

140. Au, B.C., Liu Y, Huang, J., Nelles, M., Arruda, A., Rothe, M., Paul, G., Schambach, A., Barber, D.L, Minden, M.D, Paige, C.J., and Medin, J.A.: Pre-Clinical Preparation and Validation of Tumor Cell-Based IL-12 Immunotherapy for Acute Myeloid Leukemia. American Society of Gene and Cell Therapy 18th Annual Meeting. May (2015).

141. McKillop, WM., Au, B.C., Moncada, C., Andreev, N., Keever-Taylor, C.A., Drobyski, W.R., Minden, M.D., Paige, C.J., and Medin, J.A.: Clinical LV design incorporating human-derived cell-fate control (suicide) elements. American Society of Gene and Cell Therapy 18th Annual Meeting. May (2015).

142. Oldham, R.A.A., Berinstein E.M., Medin J.A.: Immunotherapeutic Targeting of AML with a Novel CD123 CAR. 8th Canadian Cancer Immunotherapy Consortium (CCIC) Symposium. May (2015).

143. Yu, F.P.S., Islam, D., Belcastro, R., Casas, J., Fabrias, G., Levade, T., Tanswell, K.A., Zhang, H., and Medin, J.A.: Impaired lung function in the acid ceramidase deficient mouse. Molec Genet and Metabol. 114:S127 (2015).

144. Berinstein, E.M., Oldham, R.A.A.,Williams, B., Keating, A., Medin, J.A.: Transduction of NK-92 Cells with a High Affinity Variant of the Fc Receptor to Enhance Antibody Dependent Cellular Cytotoxicity. 8th Canadian Cancer Immunotherapy Consortium (CCIC) Symposium. May (2015).